Document:

EX-10.1

 Exhibit 10.1 

ASSET PURCHASE AGREEMENT 

This Asset Purchase Agreement (this “Agreement”) is made and entered into as of January 21, 2014
(“Effective Date”) between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 105 Digital Drive, Novato, CA 94949, (“BioMarin”) and Repligen Corportion, a Delaware corporation with
offices at 41 Seyon Street, Building 1, Suite 100, Waltham, MA 02453 (“Repligen”). Repligen and BioMarin shall also be referred to herein individually as “Party” and collectively as “Parties”.

 WHEREAS, Repligen controls certain intellectual property relating to proprietary histone
deacetylase (“HDAC”) inhibitors, and has a license to certain other intellectual property related to the same subject matter under the Scripps Agreement (as defined below); and 

WHEREAS, BioMarin and Repligen desire to enter into this Agreement under which BioMarin will acquire Repligen’s
intellectual property assets in such HDAC inhibitors and assume Repligen’s rights and obligations under the Scripps Agreement. 

Now, THEREFORE, in consideration of the foregoing and the mutual covenants and premises contained in this Agreement, the
receipt and sufficiency of which are hereby expressly acknowledged, the Parties hereto agree as follows: 
  

	1.	DEFINITIONS. 

 In this Agreement, the following words and expressions shall be construed
as follows: 
 1.1 “Affiliate” means any person, corporation, company, partnership, joint venture, firm or other entity
which controls, is controlled by or is under common control with a Party. For purposes of this Section 1.1, “control” will mean (i) in the case of corporate entities, direct or indirect ownership of at least fifty percent
(50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the stock or shares entitled to vote for the election of directors and (ii) in the case of non-corporate
entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. 

1.2 “Back-up Product” means any Product other than the [**Confidential Treatment Requested**] 

1.3 “Chronic Toxicology Studies” means a GLP study with a [**Confidential Treatment Requested**] 

1.4 “[**Confidential Treatment Requested**] Histone Deacetylase Inhibitor” means an inhibitor with [**Confidential
Treatment Requested**] activity towards [**Confidential Treatment Requested**] 
 1.5 “Combination Product” means
either: (a) any pharmaceutical product that consists of a Product and at least one other active ingredient that is not a Product; or (b) any combination of a Product and another pharmaceutical product that contains at least one other
active ingredient that is not a Product where, in each case, such products are not formulated together but are sold together as a single product and invoiced as one product. 

 1.6 “Commercially Reasonable Efforts” means, in reference to a Party’s
obligation to perform or achieve a specified obligation or goal with respect to a particular compound or product, efforts that are comparable in quality and scope to those efforts that are generally used by such Party to perform or achieve a
comparable obligation or goal with respect to a pharmaceutical product in respect of which such Party owes no royalties or similar third party payments, which has the same regulatory requirements or status (for example, requires a prescription or is
available over-the-counter), is at a comparable stage of development or product life to the relevant compound or product, and that has similar market potential to the relevant compound or product, taking into account relative safety and efficacy,
product profile, the competitiveness of the marketplace, the proprietary position of the compound or product and relevant regulatory circumstances. Without limiting the foregoing, Commercially Reasonable Efforts require that a Party:
[**Confidential Treatment Requested**] 
 1.7 “Confidential Information” has the meaning set forth in Section 9
of this Agreement. 
 1.8 “Control” or “Controlled” means: (i) with respect to any Information
and/or Patents, the possession by a Party of the ability to grant a license or sublicense of such Information and/or Patents as provided herein, and/or (ii) with respect to proprietary materials, the possession by a Party of the ability to
supply such proprietary materials to the other Party as provided herein, in each case without violating the terms of any agreement or arrangement between such Party and any third party. 

1.9 “[**Confidential Treatment Requested**] Product” has the meaning set forth in Section 4.2(c).  

1.10 “Dollar” means a U.S. dollar, and “$” shall be interpreted accordingly. 

1.11 “EMA” means the European Medicines Agency or any successor entity. 

1.12 “Executive Officer” means, with respect to Repligen, its Chief Executive Officer, and with respect to BioMarin, its Chief
Executive Officer. 
 1.13 “EU” means the European Union, as its membership may be altered from time to time, and any
successor thereto. 
 1.14 “FDA” means the U.S. Food and Drug Administration or any successor entity. 

1.15 “First Commercial Sale” means, with respect to a particular Product in a particular country, the first arms-length sale
to a Third Party of such Product in such country after Regulatory Approval has been obtained in such country. First Commercial Sale shall not include any transfer or disposition of a sample or for charitable purposes (including, without limitation,
pursuant to an early access, compassionate use, named patient, indigent access or patient assistance program), or for preclinical, clinical or regulatory purposes. 

  
 2 

 1.16 “First FA Library Compound” means the first Library Compound, other than
the [**Confidential Treatment Requested**] 
 1.17 “First FA Library Product” means a Library Product that
[**Confidential Treatment Requested**] 
 1.18 “First Non-FA Library Compound” means the first Library Compound,
[**Confidential Treatment Requested**]. For the avoidance of doubt, the [**Confidential Treatment Requested**] 
 1.19
“First Non-FA Library Product” means a Library Product that contains the First Non-FA Library Compound. 
 1.20
“Generic Product” means, with respect to a Product in a particular country, another pharmaceutical product that: [**Confidential Treatment Requested**] 

1.21 “Governmental Authority” means any multi-national, federal, state, local, municipal, provincial or other governmental
authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

1.22 “IND” means (a) an Investigational New Drug Application as defined in the FD&C Act and applicable regulations
promulgated thereunder by the FDA, or (b) the equivalent application to the equivalent agency in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans
in such jurisdiction. 
 1.23 “Indication” means a medically distinct and differentiable human disease, condition or
disorder. For clarity, all forms of Friedreich’s Ataxia shall be considered the same Indication. 
 1.24
“Information” means any data, results, technology, business information and information of any type whatsoever, in any tangible or intangible form, including, without limitation, know-how, trade secrets, practices, techniques, methods,
processes, inventions, improvements, developments, specifications, formulations, formulae, materials or compositions of matter of any type or kind (patentable or otherwise), software, algorithms, marketing reports, expertise, technology, test data
(including pharmacological, biological, chemical, biochemical, toxicological, preclinical and clinical test data), analytical and quality control data, stability data, other study data and procedures. 

1.25 “Laws” means any law, statute, rule, regulation, ordinance or other pronouncement having the effect of law of any
federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 
 1.26
“Library Compound” means any compound [**Confidential Treatment Requested**] 

  
 3 

 1.27 “Library Product” means any Product containing a Library Compound as an
active pharmaceutical ingredient. 
 1.28 “Marketing Authorization Application” or “MAA” means an
application to the appropriate Regulatory Authority for approval to market a Product in any particular jurisdiction, such as an NDA in the U.S. 

1.29 “NDA” means a New Drug Application, Abbreviated New Drug Application, Biologics License Application, or similar
application which is required to be filed with the FDA to obtain a marketing approval of a Product in the United States. 
 1.30
“Net Sales” means, with respect to a particular time period, the total amounts invoiced by BioMarin, its Affiliates and their respective licensees for sales of Products made during such time period to unrelated Third Parties,
less the following deductions to the extent actually allowed or incurred with respect to such sales: 
  

	 	(a)	[**Confidential Treatment Requested**] 

  

	 	(b)	[**Confidential Treatment Requested**] 

  

	 	(c)	[**Confidential Treatment Requested**] 

  

	 	(d)	[**Confidential Treatment Requested**] 

  

	 	(e)	[**Confidential Treatment Requested**] 

  

	 	(f)	[**Confidential Treatment Requested**] 

 Each of the deductions set forth above shall be reasonable and
customary, and in accordance with United States Generally Accepted Accounting Principles (GAAP). Notwithstanding the foregoing, amounts billed by BioMarin, its Affiliates, or their respective licensees for the sale of Products among BioMarin, its
Affiliates or their respective licensees for resale shall not be included in the computation of Net Sales hereunder. For purposes of determining Net Sales, the Products shall be deemed to be sold when shipped and a “sale” shall not include
reasonable transfers or dispositions as samples or for charitable purposes (including, without limitation, pursuant to an early access, compassionate use, named patient, indigent access or patient assistance program), or transfers or dispositions
for preclinical, clinical or regulatory purposes. 
 Net Sales for Combination Products, for the purpose of calculating BioMarin’s payment obligations
hereunder, shall be determined as follows: 
 (i) In the event one or more Products are sold as part of a Combination Product in a
particular country, and all pharmaceutical products contained in the Combination Product are sold separately in such country, the Net Sales of such Product(s), for the purposes of determining payments based on Net Sales, shall be determined by
[**Confidential Treatment Requested**] in each case during the applicable Net Sales reporting period. 

  
 4 

 (ii) In the event one or more Products are sold as part of a Combination Product and are
sold separately in finished form in such country, but the other pharmaceutical product(s) included in the Combination Product are not sold separately in finished form in such country, the Net Sales of the Product, for the purposes of determining
payments based on Net Sales, shall be determined by [**Confidential Treatment Requested**] in each case during the applicable Net Sales reporting period. Under no circumstances can [**Confidential Treatment Requested**] exceed
[**Confidential Treatment Requested**]. 
 (iii) In the event that one or more of the Product(s) are not sold
separately in finished form in the country, but all of the other pharmaceutical product(s) included in the Combination Product in such country are sold separately, the Net Sales of the Product, for the purposes of determining payments based on Net
Sales, shall be determined by [**Confidential Treatment Requested**] in each case during the applicable Net Sales reporting period. 

(iv) In the event that the Net Sales of the Product(s) when included in a Combination Product cannot be determined using the methods
above, Net Sales for the purposes of determining payments based on Net Sales shall be decided by BioMarin and Repligen, acting in good faith, on the basis of the respective fair market values of the Product(s) and all other pharmaceutical products
included in such Combination Product. 
 1.31 “Non-FA Indication” means an Indication other than Friedreich’s
Ataxia. 
 1.32 “Patents” means (a) pending provisional and non-provisional patent applications, issued patents,
utility models and designs; (b) continuations, continued prosecution applications, continuations-in-part, divisions, reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, extensions, renewals,
supplementary protection certificates, and term restorations of any of the foregoing and (c) any foreign equivalent or counterpart of any of the foregoing. 

1.33 “Phase 1 Clinical Trial” means a human clinical trial of a Product, the principal purpose of which is to evaluate safety
in healthy individuals or patients, to determine pharmacokinetic parameters and other key pharmaceutical properties of such Product (including absorption, metabolism, and elimination), or to determine the appropriate range of doses to evaluate in
further clinical trials, in each case as described in 21 C.F.R. § 312.21(a), or a similar clinical study prescribed by the Regulatory Authorities in a country other than the United States. 

1.34 “Phase 2 Clinical Trial” means a human clinical trial of a Product, the principal purpose of which is to evaluate the
effectiveness of such Product in the target patient population, as described in 21 C.F.R. § 312.21(b), or a similar clinical study prescribed by the Regulatory Authorities in a country other than the United States. A Phase 2/3 trial shall be
considered to be both a Phase 2 Clinical Trial and a Phase 3 Clinical Trial. 
 1.35 “Phase 3 Clinical Trial” means a
human clinical trial of a Product on a sufficient number of subjects that is designed to: (a) establish that such Product is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are
associated with such Product in the dosage range to be prescribed; and (c) support Regulatory Approval of such  

  
 5 

 
Product, as described in 21 C.F.R. § 312.12(c), or a similar clinical study prescribed by the Regulatory Authorities in a country other than the United States. A Phase 2/3 trial shall be
considered to be both a Phase 2 Clinical Trial and a Phase 3 Clinical Trial. Any study publicly described as a pivotal study by BioMarin shall be considered a Phase 3 Clinical Trial. 

1.36 “Pricing Approval” means such governmental approval, agreement, determination or decision establishing prices for a
Product that can be charged or reimbursed in regulatory jurisdictions where the applicable Governmental Authorities approve or determine the price or reimbursement of pharmaceutical products. 

1.37 “Product” means, on a product-by-product and country-by-country basis, a pharmaceutical formulation for use in diagnosis,
treatment, prevention, or amelioration of any Indication in humans that includes or incorporates, as the active pharmaceutical ingredient, a [**Confidential Treatment Requested**] Histone Deacetylase Inhibitor that:
(a) [**Confidential Treatment Requested**], (b) [**Confidential Treatment Requested**], or (c) [**Confidential Treatment Requested**]; provided, that in the event [**Confidential Treatment Requested**]. For
the avoidance of doubt, any product that was licensed or acquired by BioMarin from a third party, or discovered by BioMarin as part of an independent development program without access to, reliance upon, or use of Repligen Confidential Information
shall not be considered a Product. 
 1.38 “Regulatory Approval” means all approvals, including Pricing Approvals and
government reimbursement approval (in each case if applicable), necessary for the commercial sale of a Product in a given country or regulatory jurisdiction. 

1.39 “Regulatory Authority” means, in a particular country or jurisdiction, any applicable Governmental Authority involved in
granting Regulatory Approval in such country or jurisdiction. 
 1.40 “Regulatory Exclusivity” means market
exclusivity granted by a Governmental Authority designed to prevent the entry of generic product(s) onto the market, including without limitation new chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan
drug exclusivity, pediatric exclusivity and 180-day generic product exclusivity, or any equivalent of the foregoing in any country in the world. 

1.41 “Regulatory Materials” means regulatory applications, submissions, notifications, communications, correspondence,
registrations, Regulatory Approvals or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to develop, manufacture, market, sell or otherwise commercialize a Product in a particular country or
jurisdiction. 
 1.42 “Repligen Know-How” means all Information or other materials in Repligen’s possession or
Control, [**Confidential Treatment Requested**]: (a) [**Confidential Treatment Requested**]; or (b) [**Confidential Treatment Requested**]. 

1.43 “Repligen Patents” means: (a) [**Confidential Treatment Requested**], and (b) [**Confidential
Treatment Requested**]. 

  
 6 

 1.44 “Repligen Technology” means Repligen Know-How and Repligen Patents.

 1.45 “Royalty Term” has the meaning set forth in Section 4.3(c). 

1.46 “Scripps Agreement” means the License Agreement, made and entered into as of April 6, 2007, by and between Repligen
and The Scripps Institute, attached hereto as Exhibit C. 
 1.47 “Scripps Patents” means the
“Licensed Patent Rights,” as defined in Section 1.4 of the Scripps Agreement. 
 1.48 “Third Party”
means any entity other than Repligen or BioMarin or an Affiliate of Repligen or BioMarin. 
 1.49 “U.S.” means the
United States of America. 
 1.50 “Valid Claim” means, with respect to any country, a claim of (a) an issued and
unexpired patent (as may be extended through supplementary protection certificate or patent term extension or the like) included within the Repligen Patents or the Scripps Patents, as the case may be, to the extent such claim has not been revoked,
held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has
not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise or (b) a pending patent application that has not been cancelled, withdrawn or abandoned; provided, however, that
if a claim of a pending patent application shall not have issued within [**Confidential Treatment Requested**] after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes
of this Agreement unless and until a patent issues with such claim[**Confidential Treatment Requested**]. 
  

	2.	TECHNOLOGY TRANSFER. 

 By March 15, 2014, Repligen shall promptly transfer to
BioMarin: (a) the Repligen Know-How, [**Confidential Treatment Requested**] (b) all documents and Information in Repligen’s possession or Control that are useful or necessary for BioMarin to file, prosecute, and maintain the
Repligen Patents and Scripps Patents; (c) the biological materials and reagents described on Exhibit D, and (d) a complete list of [**Confidential Treatment Requested**]. For clarity, clause (a) above shall include all
[**Confidential Treatment Requested**] in the [**Confidential Treatment Requested**] and [**Confidential Treatment Requested**] [**Confidential Treatment Requested**], as described in Exhibit E. 

 

	3.	ASSIGNMENT OF TRANSFERRED ASSETS. 

 3.1 Assignment of Repligen Technology and
Scripps Patents. Repligen hereby sells, assigns, transfers, conveys, and delivers to BioMarin, and BioMarin hereby purchases, accepts, and acquires from Repligen, all of Repligen’s right, title and interest in and to: (i) the Repligen
Technology; and (ii) the Scripps Agreement. Within [**Confidential Treatment Requested**] of the Effective Date, Repligen shall deliver appropriate documentation to  

  
 7 

 
BioMarin evidencing such assignment, which documentation shall be in appropriate form for recording such assignments with the relevant patent offices. After the end of such [**Confidential
Treatment Requested**] period, Repligen will promptly execute all other documents that BioMarin delivers to Repligen that are reasonably necessary to perfect or evidence such assignment to BioMarin. BioMarin does not assume, shall not take
subject to, and shall not be liable for any liabilities or obligations of any kind or nature, whether absolute, contingent, accrued, known or unknown, of Repligen or any Affiliate of Repligen related to the ownership of the Repligen Technology and
the Scripps Patents prior to the Effective Date; and such liabilities and obligations shall remain the responsibility of Repligen. Furthermore, Repligen shall continue to be responsible for all Third Party agreements and obligations not assigned to
BioMarin under this Agreement, and BioMarin shall have no responsibility or liability for such agreements and obligations. 
 3.2
No Implied Licenses. No right or license under any Information or Patents of BioMarin, the Repligen Technology, or the Scripps Patents is granted or shall be granted by implication or estoppel. All such rights or licenses are or shall be granted
only as expressly provided in this Agreement. 
 3.3 Exclusivity. For a period of [**Confidential Treatment Requested**]
from the Effective Date, Repligen and its Affiliates shall not (directly or indirectly, and either with or without a bona fide Third Party collaborator) [**Confidential Treatment Requested**]. Upon Repligen’s or its Affiliate’s
material breach of this Section 3.3, BioMarin’s payment obligations under Section 4.2 and 4.3 shall terminate. 
  

	4.	PAYMENTS. 

 4.1 Upfront Payment. BioMarin shall pay to Repligen a
non-refundable, non-creditable cash payment of Two Million Dollars ($2,000,000) within fifteen (15) days after the Effective Date. In addition, upon BioMarin’s acceptance that Repligen has completed the technology transfer required under
Article 2, BioMarin shall pay Repligen $[**Confidential Treatment Requested**] to reimburse Repligen for the cost of the studies set forth in Exhibit E. 

4.2 Development Milestone Payments. 

(a) Any [**Confidential Treatment Requested**]. Within [**Confidential Treatment Requested**] after the first achievement by
BioMarin or its Affiliate or licensee of the development milestone event set forth below with respect to [**Confidential Treatment Requested**], BioMarin shall pay to Repligen the corresponding milestone payment set forth below: 

[**Confidential Treatment Requested**] 

  
 8 

			
	 Milestone Event
	  	 Milestone Payment

	 Enrollment of the first patient in the first [**Confidential Treatment Requested**] for treatment of Friedreich’s Ataxia:

 
 [**Confidential Treatment Requested**]

 
 [**Confidential Treatment Requested**]

 
 [**Confidential Treatment Requested**]

 
 [**Confidential Treatment Requested**]

 
 [**Confidential Treatment Requested**]
	  	  
  

$[**Confidential Treatment Requested**]
  

$[**Confidential Treatment Requested**]
  

$[**Confidential Treatment Requested**]
  

$[**Confidential Treatment Requested**]
  

$[**Confidential Treatment Requested**]

 For the avoidance of doubt, the milestone payment in this Section 4.2(a) is in addition to any milestones payable in
section 4.2(b) or 4.2(c). 
 (b) First FA Library Product. Within [**Confidential Treatment Requested**] days after the first
achievement by BioMarin or its Affiliate or licensee of each development milestone event set forth below with respect to the First FA Library Product to achieve the relevant development milestone event, BioMarin shall pay to Repligen the
corresponding milestone payment set forth below: 
  

					
	 	  	 Milestone Event
	  	 Milestone Payment

	 (i)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (ii)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (iii)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (iv)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]

  
 9 

					
	 	  	 Milestone Event
	  	 Milestone Payment

	 (v)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (vi)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (vii)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (viii)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (ix)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (x)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	 (xi)
	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]

  

	1 	Each of the indicated milestones shall be payable [**Confidential Treatment Requested**]. Such milestone(s) shall not be payable [**Confidential Treatment Requested**]. For example, [**Confidential
Treatment Requested**] then [**Confidential Treatment Requested**]. 

 In the event that a milestone event specified in Sections
4.2(b)(ii)—(iv) is achieved prior to one or more preceding Milestone Events (as determined by the order in which the Milestone Events are specified above), then all such preceding unachieved Milestone Events will be considered achieved and
the related unpaid Milestone Payments shall be due. In the event that either Milestone Event specified in Section 4.2(b)(v) or (vi) is achieved, then all preceding unachieved Milestone Events specified in Sections
4.2(b)(i)—(iv) will be considered achieved and the related unpaid Milestone Payments shall be due. In the event that the milestone event specified in 4.2(b)(viii) is achieved, then the Milestone Events in Sections 4.2(b)(i)-(iv) and
(vi) shall be considered achieved and, if unpaid, the corresponding Milestone Payments shall be due. In the event that a milestone event specified in Sections 4.2(b)(x) or (xi) is achieved, then the Milestone Event in
Section 4.2(b)(ix) will be considered achieved and, if unpaid, the corresponding Milestone Payment shall be due. 

  
 10 

 Except as expressly set forth in Note 1 above, each milestone set forth in the table above shall be
payable [**Confidential Treatment Requested**]. The maximum amount payable for the First FA Library Product is $[**Confidential Treatment Requested**] for Friedreich’s Ataxia and $[**Confidential Treatment Requested**] for
each of two Non-FA Indications, for maximum total development milestone payments under this Section 4.2(a) of $[**Confidential Treatment Requested**]. 

(c) First Non-FA Library Product and Back-up Products. Within [**Confidential Treatment Requested**] days after the first
achievement by BioMarin or its Affiliate or licensee of each development milestone event set forth below with respect to the First Non-FA Library Product and a Back-up Product, BioMarin shall, in each such case, pay to Repligen the corresponding
milestone payment set forth below: 
  

					
	 	  	 Milestone Event
	  	Milestone Payment
	(i)	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	(ii)	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	(iii)	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	(iv)	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	(v)	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	(vi)	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	(vii)	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]
			
	(viii)	  	[**Confidential Treatment Requested**]	  	$[**Confidential Treatment Requested**]

  
 11 

	2 	In the event the first Indication is [**Confidential Treatment Requested**] and the [**Confidential Treatment Requested**] has already achieved this milestone, the milestone payment indicated in this
Section 4.2(c) shall not be payable unless and until it is achieved by [**Confidential Treatment Requested**] or a [**Confidential Treatment Requested**] in a [**Confidential Treatment Requested**].

	3 	Such milestone(s) shall not be payable in the event the [**Confidential Treatment Requested**] has achieved the [**Confidential Treatment Requested**] in the same Indication. For example, if the
[**Confidential Treatment Requested**] achieves the milestone in [**Confidential Treatment Requested**], and the [**Confidential Treatment Requested**] later achieves the milestone in [**Confidential Treatment
Requested**] in the same Indication, then no payment shall be due for the milestone in [**Confidential Treatment Requested**]. 

With respect to the First FA Library Product or a given Back-up Product: 

(1) in the event that a milestone event [**Confidential Treatment Requested**] is achieved prior to one or more preceding Milestone
Events (as determined by the order in which the Milestone Events are specified above), then all such preceding unachieved Milestone Events will be considered achieved and the related unpaid Milestone Payments shall be due; 

(2) in the event that either Milestone Event [**Confidential Treatment Requested**] is achieved, then all preceding unachieved
Milestone Events specified in Sections 4.2(c)(i)—(iii) will be considered achieved and the related unpaid Milestone Payments shall be due; and 

(3) in the event that a milestone event specified in [**Confidential Treatment Requested**] is achieved, then the Milestone Event in
[**Confidential Treatment Requested**] will be considered achieved and, if unpaid, the corresponding Milestone Payment shall be due. 
 Each
milestone set forth in the table above shall be payable [**Confidential Treatment Requested**], regardless of how many Products achieve such milestone and regardless of whether the same Product achieves such milestone more than once. The
maximum amount payable under this Section 4.2(c) for a single Product (i.e. either the First Non-FA Library Product or a Back-up Product) is $[**Confidential Treatment Requested**] for [**Confidential Treatment Requested**]
Indication and $[**Confidential Treatment Requested**] for [**Confidential Treatment Requested**] Indication for a single Product, for maximum total development milestone payments under this Section 4.2(c) of $[**Confidential
Treatment Requested**]. 

  
 12 

 In the event a Back-Up Product is a “Product” [**Confidential Treatment Requested**] (a
“[**Confidential Treatment Requested**] Product”), then the milestones payable under this section for such Back-Up Product shall [**Confidential Treatment Requested**] as follows: 

 

			
	 Enrollment of the first patient in [**Confidential

Treatment Requested**] occurs:
	  	 Percent of applicable

milestone payable

	[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%
		
	[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%
		
	[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%
		
	[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%

 4.3 Royalty Payments. 

(a) First FA Library Product and First Non-FA Library Product. For the First FA Library Product and the First Non-FA Library Product,
BioMarin shall pay to Repligen non-refundable, non-creditable royalty payments during the applicable Royalty Term, as calculated (i) by multiplying the applicable royalty rate set forth below by the corresponding amount of incremental Net Sales
of such Products in the applicable calendar year and (ii) by subsequently making all applicable adjustments in accordance with Section 4.3(d). 
  

			
	 Annual Net Sales
	  	 Royalty Rate

	For that portion of annual Net Sales that is less than or equal to $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%
		
	For that portion of annual Net Sales that is greater than $[**Confidential Treatment Requested**] but less than or equal to $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%
		
	For that portion of annual Net Sales that is greater than $[**Confidential Treatment Requested**] but less than or equal to $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%
		
	For that portion of annual Net Sales that is greater than $[**Confidential Treatment Requested**] but less than or equal to $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%
		
	For that portion of annual Net Sales that is greater than $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%

  
 13 

 (b) Back-up Products. For Back-up Products, BioMarin shall pay to Repligen non-refundable,
non-creditable royalty payments during the applicable Royalty Term, as calculated (i) by multiplying the applicable royalty rate set forth below by the corresponding amount of incremental Net Sales of such Products in the applicable calendar
year and (ii) by subsequently making all applicable adjustments in accordance with Section 4.3(d). 
  

					
	 Annual Net Sales of Back-up Products
	  	 Royalty Rate

for Back-up
 Products
other
 than Derived

Products
	  	 Royalty Rate

for Derived
 Products4

			
	For that portion of annual Net Sales that is less than or equal to $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%	  	[**Confidential Treatment Requested**]%
			
	For that portion of annual Net Sales that is greater than $[**Confidential Treatment Requested**] but less than or equal to $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%	  	[**Confidential Treatment Requested**]%
			
	For that portion of annual Net Sales that is greater than $[**Confidential Treatment Requested**] but less than or equal to $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%	  	[**Confidential Treatment Requested**]%
			
	For that portion of annual Net Sales that is greater than $[**Confidential Treatment Requested**] but less than or equal to $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%	  	[**Confidential Treatment Requested**]%
			
	For that portion of annual Net Sales that is greater than $[**Confidential Treatment Requested**]	  	[**Confidential Treatment Requested**]%	  	[**Confidential Treatment Requested**]%

  

	4 	Royalties shall only be payable for [**Confidential Treatment Requested**] Products for which enrollment of the first patient in [**Confidential Treatment Requested**] occurs prior to [**Confidential
Treatment Requested**]. For any [**Confidential Treatment Requested**] Product for which enrollment of the first patient in [**Confidential Treatment Requested**] occurs on or after [**Confidential Treatment Requested**],
the royalty rate will be [**Confidential Treatment Requested**] percent ([**Confidential Treatment Requested**]%). [**Confidential Treatment Requested**] 

  
 14 

 (c) Royalty Term. Royalties shall be paid under this Section 4.3, on a
country-by-country and Product-by-Product basis, during the period of time beginning from the First Commercial Sale of such Product in such country until the later of: (i) the expiration of Regulatory Exclusivity for such Product in such
country; (ii) the expiration of the last-to-expire Valid Claim claiming such Product in such country; or (iii) [**Confidential Treatment Requested**] (the “Royalty Term”). In the event that, in a given jurisdiction,
there is no Valid Claim claiming a given Product [**Confidential Treatment Requested**] but [**Confidential Treatment Requested**], then the royalty payable by BioMarin shall be [**Confidential Treatment Requested**] percent
([**Confidential Treatment Requested**]%) of the royalty rate otherwise applicable under Section 4.3(a) or Section 4.3(b). 

(d) Royalty Adjustments. To the extent applicable, BioMarin may apply any and all of the following adjustments to the royalty payments
due to Repligen under this Section 4.3(d), and these deductions shall apply in addition to any royalty deduction applied under Section 4.3(c)(iii). 

(i) Third Party Intellectual Property. If BioMarin, in its reasonable judgment, is required to obtain a license from any Third Party
under any intellectual property owned or controlled by such Third Party that would be infringed or misappropriated by the importation, sale, manufacture or use of a Product, then, the royalty payment that would otherwise be due pursuant to this
Section 4.3 shall be reduced by [**Confidential Treatment Requested**] percent ([**Confidential Treatment Requested**]%) of the amount of the royalty payments made by BioMarin to such Third Party; provided, however, that the
royalty payment that would otherwise be due pursuant to this Section 4.3 with respect to a particular calendar quarter [**Confidential Treatment Requested**]. BioMarin may carry forward to a subsequent calendar quarter any amounts that
it was not able to deduct as a result of the foregoing proviso.  
 (ii) Generic Product. During the portion of the applicable
Royalty Term in a particular country where there are one or more products being sold in such country that are Generic Products with respect to a particular Product, then the royalty payment that would otherwise be due pursuant to this
Section 4.3 with respect to such Product in such country shall be reduced by [**Confidential Treatment Requested**] percent ([**Confidential Treatment Requested**]%). [**Confidential Treatment Requested**] 

(iii) Royalty [**Confidential Treatment Requested**]. BioMarin may [**Confidential Treatment Requested**], applicable to
[**Confidential Treatment Requested**] and [**Confidential Treatment Requested**], by [**Confidential Treatment Requested**], subject to [**Confidential Treatment Requested**], provided such [**Confidential Treatment
Requested**] shall not [**Confidential Treatment Requested**] above, by: (a) [**Confidential Treatment Requested**], or (b) [**Confidential Treatment Requested**]. Only if BioMarin first exercises
[**Confidential Treatment Requested**], then BioMarin may [**Confidential Treatment Requested**], subject to [**Confidential Treatment Requested**], by: (a) [**Confidential Treatment Requested**], or
(b) [**Confidential Treatment Requested**]. BioMarin may [**Confidential Treatment Requested**], subject to [**Confidential Treatment Requested**], provided such [**Confidential Treatment Requested**], by
[**Confidential Treatment Requested**] per [**Confidential Treatment Requested**], or [**Confidential Treatment Requested**] per [**Confidential Treatment Requested**]. 

  
 15 

 4.4 Royalty Reports and Payments. Within [**Confidential Treatment Requested**]
days following the end of each calendar quarter, commencing with the calendar quarter in which the First Commercial Sale of any Product occurs, BioMarin shall provide Repligen with a report containing the following information for the applicable
calendar quarter, on a country-by-country and Product-by-Product basis: [**Confidential Treatment Requested**]. Concurrent with the delivery of the applicable quarterly report, BioMarin shall pay in Dollars all amounts due to Repligen
pursuant to Section 4.3 with respect to Net Sales by BioMarin, its Affiliates and their respective sublicensees for such calendar quarter. 

4.5 Obligations to Third Parties. BioMarin shall be responsible for all [**Confidential Treatment Requested**]. BioMarin
acknowledges that anything herein to the contrary notwithstanding, the rights granted to BioMarin to and under the Scripps Agreement, including rights to the Scripps Patents and any other intellectual property of Scripps, are in all cases subject to
the terms, conditions and limitations set forth in the Scripps Agreement. 
 4.6 Payment Method. All payments due to Repligen
hereunder shall be made in Dollars by wire transfer of immediately available funds into an account designated by Repligen. 
 4.7
Records; Audits. BioMarin and its Affiliates and sublicensees will maintain complete and accurate records in sufficient detail to permit Repligen to confirm the accuracy of the calculation of royalty payments and the achievement of milestone
events. Upon reasonable prior notice, such records shall be available during regular business hours for a period of [**Confidential Treatment Requested**] years from the end of the calendar year to which they pertain for examination, and not
more often than [**Confidential Treatment Requested**] each calendar year, by an independent certified public accountant selected by Repligen and reasonably acceptable to BioMarin, for the sole purpose of verifying the accuracy of the
previously unaudited financial reports furnished by BioMarin pursuant to this Agreement. Any such auditor shall not disclose BioMarin’s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the
financial reports furnished by BioMarin or the amount of payments due by BioMarin to Repligen under this Agreement. Any amounts shown to be owed but unpaid shall be paid within [**Confidential Treatment Requested**] days from the
accountant’s report. Repligen shall bear the full cost of such audit unless such audit discloses an underpayment by the BioMarin of more than [**Confidential Treatment Requested**] percent ([**Confidential Treatment Requested**]%)
of the amount due, in which case BioMarin shall bear the reasonable cost of such audit. 
 4.8 Taxes. 

(a) Taxes on Income. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly
or indirectly from the efforts of the Parties under this Agreement. 

  
 16 

 (b) Tax Cooperation. The Parties agree to cooperate with one another and use reasonable
efforts to reduce or eliminate tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by BioMarin to Repligen under this Agreement. To the extent BioMarin is required to deduct and withhold taxes
on any payment to Repligen, BioMarin shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Repligen an official tax certificate or other evidence of such withholding sufficient to enable
Repligen to claim such payment of taxes. Repligen shall provide BioMarin any tax forms that may be reasonably necessary in order for BioMarin not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.
Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery
to be for the benefit of the Party bearing such withholding tax or value added tax. 
  

	5.	REPRESENTATIONS AND WARRANTIES. 

 5.1 Each Party hereby represents and
warrants to the other Party as follows: 
 (a) It is a company or corporation duly organized, validly existing, and in good
standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as
contemplated in this Agreement; 
 (b) It has the corporate power and authority and the legal right to enter into this
Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder; and (iii) the
Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms; and 

(c) It is not a party to any agreement that would prevent it from granting the rights granted to the other Party under this Agreement or
performing its obligations under the Agreement. 
 5.2 Repligen hereby represents, warrants and covenants that: 

(a) It has sufficient legal or beneficial title, ownership or license, free and clear from any mortgages, pledges, liens, security
interests, conditional and installment sale agreements, encumbrances, charges or claims of any kind, of the Repligen Technology and the Scripps Patents to grant the assignments to BioMarin as purported to be granted pursuant to this Agreement. As of
the Effective Date, Repligen is the sole owner of all right, title and interest in and to (free and clear from any mortgages, pledges, liens, security interests, conditional and installment sale agreements, encumbrances, charges or claims of any
kind) of the Repligen Technology identified in Exhibit G (“Owned Repligen Technology”; all remaining Repligen Technology is “Licensed Repligen Technology”). 

(b) It has not received any written notice from any Third Party asserting or alleging that any research or development of the Products
by Repligen prior to the Effective Date infringed or misappropriated the intellectual property rights (including any trade secrets) of such Third Party. The Repligen Technology and the Scripps Patents existing as of the Effective Date were not
obtained in violation of any contractual or fiduciary obligation owed by Repligen or its employees or agents to any Third Party. 

  
 17 

 (c) To Repligen’s knowledge, (i) the research, development, manufacture, use and
sale after the Effective Date of Products can be carried out in the manner reasonably contemplated as of the Effective Date, and (ii) the research, development, manufacture and use prior to the Effective Date of Products by or on behalf of
Repligen has been carried out, without infringing any published patent applications (evaluating such patent applications as though they were issued with the claims as published as of the Effective Date) or issued patents owned or controlled by a
Third Party. 
 (d) There are no pending, and to Repligen’s knowledge no threatened, adverse actions, suits or proceedings
against Repligen involving Repligen Technology, Scripps Patents, or the Products. 
 (e) To Repligen’s knowledge, there are no
activities by Third Parties that would constitute infringement or misappropriation of the Repligen Technology or Scripps Patents existing as of the Effective Date (in the case of pending claims, evaluating them as if issued as of the Effective
Date). 
 (f) It has not conveyed or licensed, and will not attempt to convey or license after the Effective Date, to a Third Party
any right, title, or interest in, to or under any Repligen Technology or Scripps Patents (including to the Scripps Agreement) which conflicts with any rights and licenses granted to BioMarin under this Agreement. 

(g) The Scripps Agreement is in full force and effect in accordance with its terms, and Repligen is not in breach of such agreement and
has not received notice from any party to the Scripps Agreement that it is in breach of any such agreement. 
 (h) To Repligen’s
knowledge, no person, other than former or current employees of Repligen who are obligated in writing to assign his/her inventions to Repligen, is an inventor of any of the inventions within the Owned Repligen Technology. 

(i) The development of Products has been conducted prior to the Effective Date by Repligen and its Affiliates and, to the knowledge of
Repligen, its independent contractors, in compliance in all material respects with all applicable Laws, including all public health, environmental, and safety provisions thereof. 

(j) It has disclosed to BioMarin all material information known to Repligen with respect to the safety and efficacy of Products as
determined from nonclinical or clinical studies. 
 (k) Exhibit B sets forth all of the Patents Controlled by Repligen or its
Affiliates as of the Effective Date that relate to Repligen’s HDAC inhibitor program, and, other than such Patents, there are no inventions described in an invention disclosure form or draft patent application relating to HDAC inhibitors in
Repligen’s or its Affiliates’ Control. 

  
 18 

 (l) All patent applications within the Repligen Patents are still pending and all issued
Patents within the Repligen Patents are in good standing and have not been abandoned. 
 (m) The Repligen Patents are not the subject
of any interference, opposition, reexamination, reissue or similar proceeding. 
  

	6.	DILIGENCE. 

 6.1 BioMarin Diligence Obligations. BioMarin shall, directly
or indirectly through one or more sublicensees or assignees, use Commercially Reasonable Efforts to commercialize [**Confidential Treatment Requested**]. BioMarin shall provide written annual reports within 30 days of each anniversary of the
Effective Date to Repligen detailing progress made with Products during such preceding annual period including [**Confidential Treatment Requested**]. For clarity, BioMarin shall have no obligation to commercialize [**Confidential
Treatment Requested**]. BioMarin’s obligations under this Section 6.1 shall terminate upon the later of: (a) expiration of the last Valid Claim within the Repligen Patents, and (b) the tenth (10th) anniversary of the Effective Date. 
 6.2 Impact of Failed Diligence.
If BioMarin is in breach of Section 6.1 and fails to cure such breach within [**Confidential Treatment Requested**] of written notice by Repligen detailing the nature of such breach, then: (a) [**Confidential Treatment
Requested**], and (b) [**Confidential Treatment Requested**]. Within [**Confidential Treatment Requested**] of Repligen’s written notice to BioMarin that [**Confidential Treatment Requested**], the Parties
[**Confidential Treatment Requested**]. As part of any such [**Confidential Treatment Requested**], Repligen shall, [**Confidential Treatment Requested**]. For clarity, BioMarin shall [**Confidential Treatment
Requested**] except [**Confidential Treatment Requested**]. 
  

	7.	INDEMNIFICATION. 

 7.1 Indemnification by Repligen. Repligen shall defend,
indemnify, and hold BioMarin and its Affiliates and their respective officers, directors, employees, and agents (the “BioMarin Indemnitees”) harmless from and against any and all damages or other amounts payable to a Third Party
claimant, as well as any reasonable attorneys’ fees and costs of litigation incurred by such BioMarin Indemnitees (collectively, “BioMarin Damages”), all to the extent resulting from any claims, suits, proceedings or causes of
action brought by such Third Party against such BioMarin Indemnitee (collectively, “BioMarin Claims”) that arise from or are based on: (a) [**Confidential Treatment Requested**]; or (b) [**Confidential Treatment
Requested**]. The foregoing indemnity obligation shall not apply to the extent that [**Confidential Treatment Requested**]. 

7.2 Indemnification by BioMarin. BioMarin shall defend, indemnify, and hold Repligen and its Affiliates and their respective officers,
directors, employees, and agents (the “Repligen Indemnitees”) harmless from and against any and all damages or other amounts payable to a Third Party claimant, as well as any reasonable attorneys’ fees and costs of litigation
incurred by such BioMarin Indemnitees (collectively, “Repligen Damages”), all to the extent resulting from any claims, suits, proceedings or causes of action brought by such Third Party 

  
 19 

 
against such Repligen Indemnitee (collectively, “Repligen Claims”) that arise from or are based on: (a) [**Confidential Treatment Requested**], or
(b) [**Confidential Treatment Requested**], or (c) [**Confidential Treatment Requested**]. The foregoing indemnity obligation shall not apply to the extent that (i) the Repligen Indemnitees fail to comply with the
indemnification procedures set forth in Section 7.3 and [**Confidential Treatment Requested**], or (ii) [**Confidential Treatment Requested**]. 

7.3 Indemnification Procedures. The Party claiming indemnity under this Article 7 (the “Indemnified Party”) shall give
written notice to the Party from whom indemnity is being sought (the “Indemnifying Party”) promptly after learning of such BioMarin Claims or Repligen Claims (as applicable) (each a “Claim”). The Indemnified Party
shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of the Claim for which indemnity is being sought. The Indemnified Party may participate in and monitor such
defense with counsel of its own choosing at its sole expense; provided, however, the Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice. [**Confidential Treatment Requested**] If
the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any
manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party shall remain responsible
to indemnify the Indemnified Party as provided in this Article 7. 
 7.4 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE
TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR LOSS OF PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING
IN THIS SECTION 6.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT [**Confidential Treatment Requested**]. 
 7.5 Insurance.
Each Party shall procure and maintain insurance adequate to cover its activities hereunder, consistent with normal business practices of prudent companies similarly situated at all times during which any Product is being clinically tested in human
subjects or commercially distributed or sold by such Party. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this Article 7. Each
Party shall provide the other Party with written evidence of such insurance upon request. 
  

	8.	INTELLECTUAL PROPERTY. 

 8.1 Patent Prosecution. 

(a) Scripps Patents. The preparation, filing, prosecution, maintenance and enforcement of the Scripps Patents will be carried out by
[**Confidential Treatment Requested**], and Repligen will have no rights or obligations with respect to such preparation, filing, prosecution, and maintenance of the Scripps Patents. 

  
 20 

 (b) Repligen Patents. BioMarin shall have the sole right to file, prosecute, and maintain
the Repligen Patents and shall use Commercially Reasonable Efforts to do so in order to support the development and commercialization of Products. Repligen shall provide BioMarin all reasonable assistance and cooperation, [**Confidential
Treatment Requested**], in BioMarin’s patent prosecution efforts with respect to such Patents, including providing any necessary powers of attorney, executing any other required documents or instruments for such prosecution and making
inventors available for consultations, declaration, examiner interviews and the like. [**Confidential Treatment Requested**] In addition, at Repligen’s request, [**Confidential Treatment Requested**] of the Repligen Patents. If
BioMarin decides to abandon any of the Repligen Patents Families based on the applications: (i) [**Confidential Treatment Requested**]; (ii) [**Confidential Treatment Requested**]; (iii) [**Confidential Treatment
Requested**]; or (iv) [**Confidential Treatment Requested**], as set forth in Exhibit B, BioMarin will notify Repligen at least [**Confidential Treatment Requested**] in advance of the event that would result in abandonment of
such Repligen Patent Family, [**Confidential Treatment Requested**] As used in this Section 8.1(b), a Repligen Patent Family means one of the applications listed in the preceding sentence and any Repligen Patent derived from and claiming
priority to such application; provided that, with respect to the provisional application, [**Confidential Treatment Requested**] A Repligen Patent Family shall be considered to be abandoned by BioMarin if BioMarin has chosen to terminate
patent prosecution of the last Valid Claim of all Repligen Patents within such Repligen Patent Family. [**Confidential Treatment Requested**] [**Confidential Treatment Requested**] 

8.2 Infringement of Repligen Patents by Third Parties. 

(a) Notification. If Repligen becomes aware of any existing or threatened infringement of any Repligen Patent by a Third Party, (an
“Infringement”), it shall promptly notify BioMarin in writing to that effect and the Parties will consult with each other regarding any actions to be taken with respect to such Infringement. 

(b) Enforcement Rights. BioMarin shall have the sole right, but not the obligation, to bring an appropriate suit or other action against
any person or entity engaged in such Infringement, [**Confidential Treatment Requested**] 
 (c) Collaboration. Repligen shall
provide to BioMarin (i) all Information available to Repligen regarding such alleged Infringement and (ii) reasonable assistance in such enforcement described in subsection (b), [**Confidential Treatment Requested**], including
joining such action as a party plaintiff if required by applicable Laws to pursue such action. 
 (d) Settlement. BioMarin
shall have the sole authority, at its sole discretion, to settle any claim, suit or action regarding an Infringment. 
 (e)
Expenses and Recoveries. [**Confidential Treatment Requested**] If BioMarin recovers monetary damages in such claim, suit or action, such recovery shall be allocated first to [**Confidential Treatment Requested**], and any
remaining amounts shall be [**Confidential Treatment Requested**]. 

  
 21 

 (f) Trademarks. BioMarin shall have the right to brand the Products using BioMarin-related
trademarks and any other trademarks and trade names it determines appropriate for the Products, which may vary by country or within a country (“Product Marks”); provided that BioMarin shall not, and shall ensure that its Affiliates
and licensees will not, make any use of the trademarks or house marks of Repligen (including Repligen’s corporate name) or any trademark confusingly similar thereto. BioMarin shall own all rights in the Product Marks and shall register and
maintain, at its own cost and expense, the Product Marks in the countries and regions that it determines reasonably necessary. 
  

	9.	TREATMENT OF CONFIDENTIAL INFORMATION. 

 For purposes of this Agreement,
“Confidential Information” shall mean all non-public scientific, technical, financial or business information which is disclosed by BioMarin to Repligen, whether in writing, or by oral or visual disclosure or presentation, and which
is treated by BioMarin as confidential or proprietary; provided, that all Repligen Technology and the Scripps Patents are also deemed to be Confidential Information of BioMarin. Notwithstanding the foregoing, “Confidential Information”
shall not include information that Repligen can demonstrate by competent evidence: 
 (a) was already known to Repligen, other
than under an obligation of confidentiality, at the time of disclosure by BioMarin; 
 (b) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to Repligen; 
 (c) became generally available to the public or
otherwise part of the public domain after its disclosure and other than through any act or omission of Repligen in breach of this Agreement; 

(d) is independently discovered or developed by Repligen (outside of the Research) without the use of Confidential Information of
BioMarin; or 
 (e) was disclosed to Repligen, on a non-confidential basis, by a third party who had no obligation to BioMarin not to
disclose such information to others. 
 Notwithstanding the foregoing, Repligen shall not be prohibited from disclosing BioMarin’s
Confidential Information to the extent such information is required to be disclosed by court order or by applicable law or government regulation; provided, however, that in such event, Repligen shall give reasonable advance notice (except where
impracticable) to BioMarin of such required disclosure and, at BioMarin’s request and expense, shall cooperate with BioMarin’s efforts to contest such disclosure, and/or to obtain a protective order or other confidential treatment of the
Confidential Information required to be disclosed. 
 Repligen agrees that it will hold Confidential Information received from BioMarin in secrecy and
confidence and will not disclose it to any Third Party, or use it for any purpose, other than for the purpose of the performance of this Agreement. Repligen further agrees that it will restrict disclosure of Confidential Information within its own
organization and Affiliates to those persons having a need to know it for the purpose of this Agreement, and that such persons will 

  
 22 

 
be advised of the obligation set forth in this Agreement and obligated in like fashion. If Repligen learns of any disclosure by it or its employees, agents, independent contractors, or Affiliates
of any Confidential Information of BioMarin not in accordance with this Section 9, Repligen shall promptly notify BioMarin of such unauthorized disclosure. 

The above obligations of Repligen with respect to its treatment of Confidential Information shall commence as of the Effective Date and
continue for a period of ten (10) years following disclosure of such Confidential Information. This Agreement shall not be construed as granting any license rights with respect to the Confidential Information. Except as otherwise required by
applicable laws and regulations or rules of any securities exchange, the Parties hereby agree that any disclosure of the terms and conditions of this Agreement shall be subject to the other Party’s prior written agreement; provided, however,
that each Party may disclose the terms and conditions of this Agreement to a prospective or actual investor, acquirer, licensee or collaborator pursuant to a written confidentiality agreement of the same or more restrictive provisions as those
contained herein, and provided further that if any such disclosure is required by laws, regulations or rules of a securities exchange, the Party required to make such disclosure shall notify the other Party of any such disclosure and shall seek
confidential treatment of portions of this Agreement where reasonably available. 
  

	10.	NOTICES. 

 10.1 All notices and statements to either Party required under
this Agreement shall be made in writing delivered via certified mail, return receipt requested, courier, provided that evidence of delivery is made, or facsimile with confirmation of such transmission addressed to such Party at the following
addresses or faxed to the appropriate numbers set forth below (with the copies to other Parties set forth below) or to such other address as may be designated from time to time: 

To Repligen: 
 Repligen
Corporation 
 41 Seyon Street 

Building 1, Suite 100 
 Waltham,
MA 02453 
 Attn: President Fax: (781)250-0115 

To BioMarin: 
 BioMarin
Pharmaceutical Inc. 
 105 Digital Drive 

Novato, CA 94949 
 Attn: General
Counsel 
 Fax: (415) 382-7889 

10.2 All notices and statements provided to a Party hereunder shall be deemed to have been given as of the date received, or at the
time of delivery of a facsimile to the relevant facsimile number above. 

  
 23 

 10.3 Each Party hereto may change its address and contact information set forth above for
the purpose of this Agreement by providing written notice to the other Party of the same from time to time. 
  

	11.	DISPUTE RESOLUTION 

 11.1 Executive Officers. Unless otherwise set
forth in this Agreement, in the event of a dispute arising under this Agreement between the Parties, the Parties shall refer such dispute to the respective Executive Officers, and such Executive Officers shall attempt in good faith to resolve such
dispute. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and, within twenty (20) days after such notice, such Executive Officers shall meet for attempted resolution by good
faith negotiations. If such Executive Officers are unable to resolve such dispute within thirty (30) days of their first meeting for such negotiations, either Party may seek to have such dispute resolved in accordance with the following
Sections 11.2 and 11.3. 
 11.2 Governing Law. This Agreement shall be governed and interpreted in accordance with the laws of
the State of California, without regard to conflict of law provisions. 
 11.3 Jurisdiction; Venue. Any dispute arising under
this Agreement, or other legal proceeding relating to this Agreement or the enforcement of any provision of this Agreement must be brought or otherwise commenced solely and exclusively in courts of competent jurisdiction located in the city of San
Francisco, California. Consistent with the preceding sentence, each of the Parties: (a) expressly and irrevocably consents and submits to the jurisdiction of the courts of competent jurisdiction in the city of San Francisco, California (and
each appellate court located in the State of California) in connection with any such legal proceeding; (b) expressly agrees that the courts of competent jurisdiction in the city of San Francisco, California shall be deemed to be a convenient
forum; and (c) expressly agrees not to assert (by way of motion, as a defense or otherwise), in any such legal proceeding commenced in the courts of competent jurisdiction in the city of San Francisco, California, any claim that such Party is
not subject personally to the jurisdiction of such court, that such legal proceeding has been brought in an inconvenient forum, that the venue of such proceeding is improper or that this Agreement or the subject matter of this Agreement may not be
enforced in or by such court. 
  

	12.	MISCELLANEOUS. 

 12.1 Acknowledgement. Each Party acknowledges that
it has negotiated and entered into this Agreement in good faith. 
 12.2 Severability. If any provision of this Agreement is
held by a court of competent jurisdiction to be invalid or unenforceable, it shall be modified, if possible, to the minimum extent necessary to make it valid and enforceable or, if such modification is not possible, it shall be stricken and the
remaining provisions shall remain in full force and effect. 
 12.3 Interpretation. 

(a) The English language of this Agreement shall govern any interpretation of or dispute regarding this Agreement. 

  
 24 

 (b) Any reference in this Agreement to a Section or Exhibit is a reference to the Sections
and Exhibits of this Agreement unless the context requires otherwise. Any reference to a Section shall be deemed to include a reference to any subsidiary Sections. 

(c) The captions of the Sections are included for reference purposes only and are not intended to be a part of the Agreement or in any
way to define, limit or describe the scope or intent of the particular provision to which they refer. 
 (d) Whenever the context
requires: the singular number shall include the plural and vice versa; the masculine gender shall include the feminine and neuter gender; the feminine gender shall include the masculine and neuter gender; and the neuter gender shall include the
feminine and masculine gender. 
 (e) The Parties agree that any rule of construction to the effect that ambiguities are to be
resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. 
 (f) As used in
this agreement “include” and “including” and variations thereof shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” 

12.4 Assignment. This Agreement shall not be assigned by either Party, without the prior written consent of the other Party; provided
that BioMarin may assign this Agreement without such consent: (i) to an Affiliate of BioMarin; (ii) in the event of a merger, consolidation or similar reorganization of BioMarin with or into a Third Party, whether by acquisition, merger,
sale of stock, change of control or otherwise, or (iii) in the event of a sale of all or substantially all of the assets of BioMarin to which this Agreement relates, this Agreement shall be assigned to or become the obligation and liability of
the acquiring entity. Any purported assignment in violation of this Section 12.4 shall be void. 
 12.5 Force Majeure. If the
performance of this Agreement or any obligation hereunder (except for the payment of money) is prevented, restricted or interfered with by reason of fire or other casualty or accident, strikes or labor disputes, inability to procure raw materials,
power or supplies, war, invasion, civil commotion or other violence, compliance with any order of any governmental authorities or any other act or conditions whatsoever beyond the reasonable control of either Party hereto, the Party so affected upon
giving a prompt notice to the other Party shall be excused from such performance to the extent of such prevention, restriction or interference; provided, however, that the Party so affected shall use commercially reasonable efforts to avoid or
remove such causes of non-performance and shall continue performance hereunder with the utmost dispatch whenever such causes are removed, to the extent commercially reasonable. 

12.6 Entirety of Agreement. This Agreement contains the entire understanding of the Parties hereto with respect to the subject matter
contained herein. There are no restrictions, promises, covenants or understandings other than those expressly set forth herein, and no rights or duties on the part of either Party are to be implied or inferred beyond those expressly herein provided
for. The Parties may, from time to time during the term of this Agreement, amend, modify, vary, waive or alter any of the provisions of this Agreement, but only by a written instrument that makes specific reference to this Agreement which is duly
executed by each Party, or in the case of waiver, by the Party or Parties waiving compliance. 

  
 25 

 12.7 Further Assurances. Each Party agrees to duly execute and deliver, or cause to be
duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, without limitation, the filing of such additional assignments, agreements, documents and instruments, that may be necessary or
as the other Party hereto may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party its rights
and remedies under, this Agreement. 
 12.8 No Partnership. For the purposes of this Agreement and all obligations to be performed
hereunder, each Party shall be, and shall be deemed to be, an independent contractor and not an agent, partner, joint venturer or employee of the other Party. Neither Party shall have authority to make any statements, representations or commitments
of any kind, or to take any action which shall be binding on the other Party, except as may be explicitly provided for herein or authorized in writing. 

12.9 Use of Other Party’s Name. Neither Party shall use the name, trademark, trade name or logo of the other Party or their
respective employee(s) in any publicity, promotion, press release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by applicable laws or
regulations. 
 12.10 Waiver. The waiver by either Party of any breach, default or omission in the performance or observance of any of
the terms of this Agreement by the other Party shall not be deemed to be a waiver of any other such breach, default or omission. Any waiver of this Agreement must be in writing and signed by the waiving Party to be effective. 

12.11 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of such
counterparts taken together shall constitute one and the same instrument. Counterparts may be signed and delivered by facsimile, each of which shall be binding when sent. 

[SIGNATURE PAGE FOLLOWS] 

  
 26 

 IN WITNESS WHEREOF, the
parties hereto, intending to be legally bound hereby, have duly executed this Asset Purchase and Research Agreement to be effective as of the Effective Date. 
  

									
	BIOMARIN PHARMACEUTICAL INC.	 		 	REPLIGEN CORPORATION 
					
	By:	 	/s/ Scott Clarke	 		 	By:	 	/s/ Howard Benjamin
	Name: Scott Clarke	 		 	Name:	 	Howard Benjamin
	Title: VP BD & Scientific Licensing	 		 	Title:	 	VP BD

 EXHIBIT A 

Repligen Library Compound 
  

			
	 Comp_ID

RGFP#
	  	Structure
	[**Confidential Treatment Requested**]

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[**Confidential Treatment
Requested**]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE
ACT OF 1934. 

 EXHIBIT B 

Repligen Patents 
  

															
	 WO (Family)

Number
	  	 F&R #
	  	 STATUS
	  	 APPLN #
	  	 FILED
	  	 PATENT #
	  	 ISSUED
	  	 TITLE

	[**Confidential Treatment Requested**]

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[**Confidential Treatment
Requested**]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE
ACT OF 1934. 

 EXHIBIT C 

Scripps Agreement 

[Omitted] 
 Already filed as Exhibit 10.18 to
Repligen Corporation’s Annual Report on Form 10-K for the year ended March 31, 2007 and incorporated herein by reference. 

 EXHIBIT D 

Biological Materials and Reagents to be Transferred to BioMarin 

Summary of chemical and biological material Repligen will transfer to BioMarin upon signing of the agreement: 

1. [**Confidential Treatment Requested**] 

2. [**Confidential Treatment Requested**] 

3. [**Confidential Treatment Requested**] 

4. [**Confidential Treatment Requested**] 

[**Confidential Treatment Requested**] 

 Note: all quantities are approximation 
  

													
		 	X g	  	 compound
 available in

bigger
 bottles in

indicated
 quantity
	  	 	  	 compound
 is no

longer
 available
	  	 	  	 compound
 available

in small
 vials

  

									
	 Comp_ID

RGFP #
	  	Structure	  	< 10 mg
vials	  	large bottles	  	not available
	[**Confidential Treatment Requested**]

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[**Confidential Treatment
Requested**]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE
ACT OF 1934. 

 EXHIBIT E 

Reimbursable Activities 

[**Confidential Treatment Requested**] 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[**Confidential Treatment Requested**]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 EXHIBIT F 

Foundation Grants 
  

							
	 Agency
	 	 Execution

Date
	 	 Goal
	 	 Amount

	[**Confidential Treatment Requested**]

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[**Confidential Treatment
Requested**]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE
ACT OF 1934. 

 EXHIBIT G 

Owned Repligen Technology 

[**Confidential Treatment Requested**] 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[**Confidential Treatment Requested**]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.EX-10.3

 Exhibit 10.3 

FOURTH AMENDMENT 
 THIS
FOURTH AMENDMENT TO LEASE (the “Amendment”) is made and entered into as of the date of final execution (“Effective Date”), by and between CENTERPOINT ACQUISITIONS LLC, a Delaware limited liability company
(“Landlord”), and REPLIGEN CORPORATION, a Delaware corporation (“Tenant”). 
 RECITALS 

 

	A.	Landlord and Tenant are parties to that certain lease dated October 10, 2001, as amended by a Letter Agreement dated May 7, 2002, a First Amendment dated June 29, 2011 (“First
Amendment”), a Second Amendment dated as of January 11, 2013, and a Third Amendment dated September 26, 2013, (collectively, the “Lease”). Pursuant to the Lease, Landlord has leased to Tenant space currently
containing 55,694 rentable square feet (the “Original Premises”) on the 1st floor of the building commonly known as 41 Seyon Street located at 41 Seyon Street, Waltham,
Massachusetts (the “Building”) for a Term that is scheduled to expire on May 31, 2023. 

  

	B.	Tenant has, by letter dated February 26, 2014, exercised its Right of First Refusal, pursuant to Section VIII of the First Amendment, to lease additional space containing approximately 19,900 rentable square feet
on the 1st and 2nd floor of the Building shown on Exhibit A, Fourth Amendment, attached hereto (the “Expansion
Space”). Landlord is willing to do the same on the following terms and conditions. 

 NOW, THEREFORE, in
consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows: 

 

	 	I.	Expansion and Effective Date. 

 Effective as of the Expansion Effective Date
(defined below), the Premises, as defined in the Lease, is increased from 55,694 rentable square feet on the 1st floor to 75,594 rentable square feet on the 1st and 2nd floors by the addition of the Expansion Space, and from and after the Expansion Effective Date, the Original Premises and the Expansion
Space, collectively, shall be deemed the Premises, as defined in the Lease. The Term for the Expansion Space shall commence on the Expansion Effective Date and end on the date that is eight (8) years and one (1) month after the Expansion
Effective Date (“Expansion Termination Date”). The Expansion Space is subject to all the terms and conditions of the Lease except as expressly modified herein and except that Tenant shall not be entitled to receive any allowances,
abatements or other financial concessions granted with respect to the Original Premises unless such concessions are expressly provided for herein with respect to the Expansion Space. 

 

	 	A.	 The Expansion Effective Date shall be the later to occur of (i) August 1, 2014 (“Target Expansion Effective Date”) and
(ii) the date upon which the Landlord Work (as defined in the Work Letter attached as Exhibit B hereto) in the Expansion Space has been substantially completed; provided, however, that if Landlord shall be delayed in substantially
completing the Landlord Work in the Expansion Space as a result of the occurrence of a Tenant Delay (defined below), then, for purposes of determining the Expansion Effective Date, the date of substantial completion shall be deemed to be the day
that said Landlord Work 

	 	
would have been substantially completed absent any such Tenant Delay(s). A “Tenant Delay” means any act or omission of Tenant or its agents, employees, vendors or contractors
that actually delays substantial completion of the Landlord Work, including, without limitation, the following: 

  

	 	1.	Tenant’s failure promptly to furnish information or approvals after Landlord’s reasonable request therefor, including the failure to prepare or approve preliminary or final plans by any applicable due date as
otherwise provided, if at all, in this Amendment or the exhibits hereto; 

  

	 	2.	Tenant’s selection of equipment or materials that have long lead times after first being informed by Landlord that the selection may result in a delay; 

 

	 	3.	Changes made by Tenant to the plans and specifications attached hereto as Exhibit B-1 and approved by Landlord, provided that Landlord has delivered to Tenant an estimate of the additional time period to effect
such changes and Tenant has approved such additional period of time; 

  

	 	4.	The performance of work in the Expansion Space by Tenant or Tenant’s contractor(s) during the performance of the Landlord Work; or 

 

	 	5.	If the performance of any portion of the Landlord Work depends on the prior or simultaneous performance of work by Tenant, a delay by Tenant or Tenant’s contractor(s) in the completion of such work.

 The Expansion Space shall be deemed to be substantially completed on the date that all Landlord Work has been performed (or
would have been performed absent any Tenant Delays), other than any minor details of construction, mechanical adjustment or any other matter, the noncompletion of which does not unreasonably interfere with Tenant’s use of the Expansion Space
and can be completed within thirty (30) days after the date of substantial completion. The parties agree to meet within three (3) Business Days after Landlord’s notice of Substantial Completion to review the Expansion Space and agree
upon the remaining punch list items to be completed. The adjustment of the Expansion Effective Date and, accordingly, the postponement of Tenant’s obligation to pay Rent on the Expansion Space shall be Tenant’s sole remedy and shall
constitute full settlement of all claims that Tenant might otherwise have against Landlord by reason of the Expansion Space not being ready for occupancy by Tenant on the Target Expansion Effective Date. 

 

	 	B.	In addition to the postponement, if any, of the Expansion Effective Date as a result of the applicability of Paragraph I.A. of this Amendment, the Expansion Effective Date shall be delayed to the extent that Landlord
fails to deliver possession of the Expansion Space for any other reason (other than Tenant Delays by Tenant), including but not limited to, holding over by prior occupants. Any such delay in the Expansion Effective Date shall not subject Landlord to
any liability for any loss or damage resulting therefrom. If the Expansion Effective Date is delayed, the Termination Date under the Lease shall not be similarly extended. 

  
 2 

	 	II.	Basic Rent. 

 Initial Rate. In addition- to Tenant’s
obligation to pay Basic Rent for the Original Premises, Tenant shall pay Basic Rent for the Expansion Space as follows: 
  

													
	 Lease Year*
	  	Annual Rate
Per Square Foot
(subject to
adjustment as
provided below)	 	  	Annual
Base Rent	 	 	Monthly
Base Rent	 
	 Lease Year 1
	  	$	18.00	  	  	$	270,000.00	** 	 	$	22,500.00	  
	 Lease Year 2
	  	$	18.00	  	  	$	306,000.00	*** 	 	$	25,500.00	  
	 Lease Year 3-5
	  	$	19.00	  	  	$	378,100.00	**** 	 	$	31,508.33	  
	 Lease Year 6-8
	  	$	20.00	  	  	$	398,000.00	**** 	 	$	33,166.67	  

  

	*	For purposes hereof, an “Lease Year” shall mean a 12 month period beginning on the Expansion Effective Date, or any anniversary of the Expansion Effective Date, except that if the Expansion Effective
Date does not fall on the first day of a calendar month, then the first Lease Year shall begin on the Expansion Effective Date, and end on the last day of the month containing the first anniversary of the Expansion Effective Date (and the Basic Rent
for such first Lease Year shall be prorated to reflect the additional days included therein), and each succeeding Lease Year shall begin on the day following the last day of the prior Lease Year. 

	**	Based on 15,000 square feet 

	***	Based on 17,000 square feet 

	****	Based on 19,900 square feet 

 All such Basic Rent and Additional Rent payable on account of
Taxes, Operating Expenses, and utilities shall be payable by Tenant in accordance with the terms of the Lease. 
 Tenant shall have no
obligation to pay Basic Rent for the first (1st) full calendar month of Lease Year 1. 
  

	 	III.	Additional Security Deposit/Letter of Credit. 

 Upon Tenant’s execution hereof, Tenant shall
deliver to Landlord an additional Security Deposit in the amount of $250,000.00 which is added to and becomes part of the Security Deposit, if any, held by Landlord as provided under Section 14.8 of the Lease as security for payment of Rent and
the performance of the other terms and conditions of the Lease by Tenant. Accordingly, simultaneously with the execution hereof, the Letter of Credit shall be increased from $250,000.00 to $450,000.00. Tenant shall provide the additional Security
Deposit by delivery to Landlord of an additional Letter of Credit in the amount of the increase (i.e., $250,000.00), or an amendment to the Letter of Credit increasing it to the increased amount (i.e., $450,000.00) or a substitute Letter of Credit
in the increased amount, whereupon Landlord shall return the original Letter of Credit. The provisions of Section 14.8(c) no longer apply to the Security Deposit and are hereby deleted from the Lease. 

  
 3 

	 	IV.	Tenant’s Proportionate Share. 

 For the period commencing with the Expansion
Effective Date and ending on the Expansion Termination Date, Tenant’s Proportionate Share for the entire Premises, including the Original Premises and Expansion Space shall be 15.12%. 

 

	 	V.	Intentionally Omitted. 

  

	 	VI.	Improvements to Expansion Space. 

  

	 	A.	Condition of Expansion Space. Tenant has inspected the Expansion Space and agrees to accept the same “as is” without any agreements, representations, understandings or obligations on the part of
Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Amendment. 

  

	 	B.	Responsibility for Improvements to Expansion Space. Landlord shall perform improvements to the Expansion Space in accordance with the Work Letter attached hereto as Exhibit B. 

 

	 	VII.	Early Access to Expansion Space. 

 During any period that Tenant shall be
permitted to enter the Expansion Space prior to the Expansion Effective Date, Tenant shall comply with all terms and provisions of the Lease, except those provisions requiring payment of Basic Rent or Additional Rent as to the Expansion Space. If
Tenant takes possession of the Expansion Space prior to the Expansion Effective Date for any reason whatsoever (other than the performance of work in the Expansion Space with Landlord’s prior approval), such possession shall be subject to all
the terms and conditions of the Lease and this Amendment, and Tenant shall pay Basic Rent and Additional Rent as applicable to the Expansion Space to Landlord on a per diem basis for each day of occupancy prior to the Expansion Effective Date. 

 

	 	VIII.	Electricity with Respect to Expansion Space. Landlord shall, as part of Landlord’s Work, install a submeter in the Expansion Space to measure the consumption of electricity in the Expansion Space and
Tenant shall reimburse Landlord for the cost of such electric current (at the same rate per kilowatt hour paid by Landlord to the utility provider from time to time) as measured by the submeter within thirty (30) days after delivery of
Landlord’s invoice therefor. 

  

	 	IX.	 Roof Terrace. Tenant shall have the right, at Tenant’s sole cost and expense, to construct a roof terrace on the roof of the
Building (“Roof Terrace”), provided that (a) no Default of Tenant has occurred and remains uncured hereunder, (b) Landlord approves in writing the location, size and appearance of the Roof Terrace, which approval may be withheld
or conditioned at Landlord’s sole discretion, (c) the Roof Terrace is in compliance with all applicable laws, codes and ordinances and Tenant has obtained all governmental permits and approvals required in connection therewith,
(d) the installation, maintenance and removal of the Roof Terrace (including, without limitation, the repair and cleaning of the 

  
 4 

	 	
roof of the Building upon removal of the Roof Terrace) is performed at Tenant’s expense in accordance with the terms and conditions governing alterations pursuant to Section 5.2 of the
Lease and Landlord’s reasonable regulations. If Landlord has approved same, Landlord agrees to cooperate with Tenant for the construction and permitting of the Roof Terrace. 

Landlord shall have the right to prescribe reasonable rules and regulations for Tenant’s use of the Roof Terrace from time to time. Such
rules shall in any event include, without limitation, that no cooking of any sort shall be permitted on the Roof Terrace, that no one shall lean over the edge of the Roof Terrace at any time, that nothing shall be hung on or displayed from the Roof
Terrace railings, that no one shall throw, sweep, shovel or otherwise dispose of anything over the edge of the Roof Terrace, and that all items placed in the Roof Terrace shall be secured such that the same cannot be blown off the Roof Terrace by
high winds. If Landlord notifies Tenant in writing that a violation of the Roof Terrace rules and regulations has occurred, and thereafter the same or a similar violation occurs beyond applicable notice and cure periods, Landlord shall have the
right to revoke Tenant’s right to use the Roof Terrace. If Tenant constructs the Roof Terrace, Tenant shall, at Tenant’s cost and expense, be responsible for (i) cleaning, repairing and maintaining the Roof Terrace throughout the Term
of the Lease and (ii) for performing any maintenance, repairs, or replacement to the Building made necessary or advisable by reason of the presence thereon of the Roof Terrace or the installation of same. 

 

	 	X.	Signage. Landlord shall, at Landlord’s cost and expense, install standard Building signage at the entrance to the Expansion Space. The initial listing of Tenant’s name shall be at Landlord’s
cost and expense. Any changes, replacements or additions by Tenant to such directory shall be at Tenant’s sole cost and expense. 

Tenant shall have the right to replace the existing Tenant sign on the north façade of the Building with a larger sign in accordance
with plans and specifications therefor approved in advance, in writing by Landlord, which approval shall not be unreasonably withheld, subject in any event to the terms and conditions of Section 5.1 (b)(ii) of the Lease. 

 

	 	XI.	Options to Extend. Tenant’s right and option to extend the Term of the Lease pursuant to Section 2.4 of the Lease, as amended by Section IX of the First Amendment, shall apply to the Expansion
Space, except that the Basic Rent for the Extension Term with respect to the Expansion Space shall be equal to 100% of the Fair Market Rental Value of the Expansion Space. The parties acknowledge that the Expansion Termination Date does not coincide
with the Extended Termination Date (as that term is defined in the First Amendment) and, therefore, agree that the time period for the exercise of the option and the periods of the extended Terms will differ with respect to the Original Premises and
the Expansion Space. 

  
 5 

	 	XII.	Right of First Offer. 

  

	 	A.	Grant of Option; Conditions. Tenant shall have the one time right of first offer (the “Right of First Offer”) with respect to any available space in the Building. Tenant’s Right of First
Offer shall be exercised as follows: at any time after Landlord has determined that available space (the “Offering Space”) exists, then, before leasing such Offering Space to a party other than the existing tenant thereof or any
party holding existing rights in such Offering Space as of the date of this Amendment. Landlord shall give Tenant written notice (the “Advice”) of the terms under which Landlord is prepared to lease the Offering Space to Tenant.
Tenant may lease such Offering Space in its entirety only, under such terms, by delivering written notice of exercise to Landlord (the “Notice of Exercise”) within 5 Business Days after the date of the Advice, except that Tenant
shall have no such Right of First Offer and Landlord need not provide Tenant with an Advice, if: 

  

	 	(i)	Tenant is in default under the Lease beyond any applicable cure periods at the time that Landlord would otherwise deliver the Advice; or 

 

	 	(ii)	the Premises, or any portion thereof, is sublet at the time Landlord would otherwise deliver the Advice (except pursuant to Section 6.1(b)); or 

 

	 	(iii)	the Lease has been assigned prior to the date Landlord would otherwise deliver the Advice (except pursuant to Section 6.1(b)); or 

 

	 	(iv)	Tenant is not occupying the Premises on the date Landlord would otherwise deliver the Advice; or 

  

	 	(v)	the Offering Space is not intended for the exclusive use of Tenant during the Term; or 

  

	 	(vi)	the existing tenant in the Offering Space is interested in extending or renewing its lease for the Offering Space or entering into a new lease for such Offering Space; or 

 

	 	(vii)	Tenant has previously leased Offering Space pursuant to this Right of First Offer; or 

  

	 	(viii)	Landlord has previously delivered an Advice to Tenant and Tenant has not timely delivered a Notice of Exercise with respect thereto (subject, however, to the provisions of Section C below). 

 

	 	B.	Terms for Offering Space. 

  

	 	(ix)	The term for the Offering Space shall commence upon the commencement date stated in the Advice and thereupon such Offering Space shall be considered a part of the Premises, provided that all of the terms stated in the
Advice shall govern Tenant’s leasing of the Offering Space and only to the extent that they do not conflict with the Advice, the terms and conditions of this Lease shall apply to the Offering Space. 

 

	 	(x)	Tenant shall pay Basic Rent and Additional Rent for the Offering Space in accordance with the terms and conditions of the Advice. 

  
 6 

	 	(xi)	The Offering Space (including improvements and personalty, if any) shall be accepted by Tenant in its condition and as-built configuration existing on the earlier of the date Tenant takes possession of the Offering
Space or as of the date the term for such Offering Space commences, unless the Advice specifies any work to be performed by Landlord in the Offering Space, in which case Landlord shall perform such work in the Offering Space. If Landlord is delayed
delivering possession of the Offering Space due to the holdover or unlawful possession of such space by any party, Landlord shall use reasonable efforts to obtain possession of the space, and the commencement of the term for the Offering Space shall
be postponed until the date Landlord delivers possession of the Offering Space to Tenant free from occupancy by any party. 

  

	 	C.	Termination of Right of First Offer. The rights of Tenant hereunder with respect to the Offering Space shall terminate on the earliest to occur of: (i) Tenant’s failure to exercise its Right of First
Offer within the 5 Business Day period provided in Section A above; (iii) the date Landlord would have provided Tenant an Advice if Tenant had not been in violation of one or more of the conditions set forth in Section A above, and
(iii) the date that Tenant exercises its Right of First Offer with respect to any portion of the Offering Space. Notwithstanding the foregoing, in the event that the Right of First Offer terminates pursuant to clause (i) above, Landlord
shall not lease the Offering Space to another party (other than the current occupant thereof) at a Net Effective Rent (defined below) less than ninety percent (90%) of the Net Effective Rent set forth in the Advice without first giving Tenant
another Advice at such lower Net Effective Rent. The term “Net Effective Rent” shall mean the net present value as reasonably determined by Landlord of the aggregate consideration, determined on an average annual basis, payable to
Landlord under the proposal at issue (i.e., either the Advice or the offer to another party, as the case may be), taking into account all base rent, additional rent, free rent, construction or other allowances, the cost of any work performed in the
Offering Space by Landlord at its expense, the length of lease term, and all other relevant economic terms. 

  

	 	D.	Offering Amendment. If Tenant exercises its Right of First Offer, Landlord shall prepare an amendment (the “Offering Amendment”) adding the Offering Space to the Premises on the terms set forth
in the Advice and reflecting the changes in the Base Rent, Rentable Square Footage of the Premises, Tenant’s Pro Rata Share and other appropriate terms. A copy of the Offering Amendment shall be sent to Tenant within a reasonable time after
Landlord’s receipt of the Notice of Exercise executed by Tenant, and Tenant shall execute and return the Offering Amendment to Landlord within 15 days thereafter, but an otherwise valid exercise of the Right of First Offer shall be fully
effective whether or not the Offering Amendment is executed. 

  

	 	E.	Subordination. Notwithstanding anything herein to the contrary, Tenant’s Right of First Offer is subject and subordinate to the expansion rights (whether such rights are designated as a right of first offer,
right of first refusal, expansion option or otherwise) of any tenant of the Building existing on the date hereof, which rights are identified on Exhibit D. 

  
 7 

	 	XIII.	Parking. In addition to Tenant’s parking rights pursuant to Section 2.3 of the Lease, as amended by Section XI of the First Amendment, Tenant shall have the right to use, on a non-exclusive,
unreserved basis, 69 parking spaces in the Parking Area. In addition to such unreserved spaces, Tenant shall have the right to use, on a reserved basis, 5 parking spaces near the North entrance to the Building in the location as shown on Exhibit
C, Fourth Amendment, attached hereto. Landlord reserves the right, in connection with any future reconfiguration of the Parking Area, to relocate such reserved spaces to a comparable location in the reconfigured Parking Area. 

 

	 	XIV.	Interior Stairs. Tenant shall have the right, at Tenant’s sole cost and expense, to interior connecting stairs between the portions of the Premises on the first and second floors
(“Stairwell”), provided that (a) the Stairwell is in compliance with all applicable laws, codes and ordinances and Tenant has obtained all governmental permits and approvals required in connection therewith, (b) the installation,
maintenance and removal of the Stairwell is performed at Tenant’s expense in accordance with plans and specifications therefor that had been approved in writing, in advance by Landlord, which approval shall not be unreasonably withheld and the
terms and conditions governing alterations pursuant to Section 5.2 of the Lease and Landlord’s reasonable regulations, and (c) Tenant has deposited with Landlord, as an additional Security Deposit, an amount reasonably estimated by
Landlord to equal the cost of removing the Stairwell and restoring the affected area of the Premises to its condition immediately preceding the installation of the Stairwell. If Landlord has approved same, Landlord agrees to cooperate with Tenant
for the construction and permitting of the Stairwell. Unless Landlord otherwise elects by written notice given at least 120 days prior to the expiration date of the Term for the Expansion Space, Tenant shall remove the Stairwell and restore the
floor slab opening in compliance with applicable codes. 

  

	 	XV.	Notices. For all purposes of the Lease, the notice address for Landlord is as follows: 

Saracen Properties LLC 
 41 Seyon
Street 
 Suite 200 
 Waltham,
MA 02453 
  

	 	XVI.	Inapplicable, Deleted and Confirmed Lease Provisions. 

  

	 	A.	Article 4 of the Lease (Commencement and Condition), Exhibit G to the Lease (Base Building Work), Exhibit B to the First Amendment (Work Letter) and Exhibit C to the First Amendment (Refusal Space) shall have no
applicability with respect to this Amendment. 

  
 8 

	 	B.	Whereas, Tenant exercised its Right of First Refusal pursuant to Section VIII of the First Amendment and Exhibit C to the First Amendment (Refusal Space), Section VIII of the First Amendment and Exhibit C to the First
Amendment are hereby deleted and are of no further force or effect. 

  

	 	XVII.	Landlord agrees to obtain from the holder of the existing mortgage on the Property a subordination, non-disturbance, and attornment agreement substantially in the form attached hereto as Exhibit E.

  

	 	XVIII.	Miscellaneous. 

  

	 	A.	This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written representations or agreements. Under no circumstances shall
Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Lease, unless
specifically set forth in this Amendment. 

  

	 	B.	Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect. 

 

	 	C.	In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control. 

 

	 	D.	Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant. Neither party shall be bound by this Amendment until both parties have
executed and delivered the same to the other party. 

  

	 	E.	The capitalized terms used in this Amendment shall have the same definitions as set forth in the Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.

  

	 	F.	Tenant hereby represents to Landlord that Tenant has dealt with no broker in connection with this Amendment. Tenant agrees to indemnify and hold Landlord, its trustees, members, principals, beneficiaries, partners,
officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents (collectively, the “Landlord Related Parties”) harmless from all claims of any broker claiming to have represented
Tenant in connection with this Amendment. Landlord hereby represents to Tenant that Landlord has dealt with no broker in connection with this Amendment. Landlord agrees to indemnify and hold Tenant, its trustees, members, principals, beneficiaries,
partners, officers, directors, employees, and agents, and the respective principals and members of any such agents (collectively, the “Tenant Related Parties”) harmless from all claims of any brokers claiming to have represented
Landlord in connection with this Amendment. 

  

	 	G.	Each signatory of this Amendment represents hereby that he or she has the authority to execute and deliver the same on behalf of the party hereto for which such signatory is acting. 

  
 9 

 [SIGNATURES ARE ON FOLLOWING PAGE] 

  
 10 

 IN WITNESS WHEREOF, Landlord and Tenant have duly executed this Amendment as of the day
and year first above written. 
  
 

 
 [Signature Page Fourth Amendment] 

 EXHIBIT A 

OUTLINE AND LOCATION OF EXPANSION SPACE 
  

 

  
 Exhibit A, Fourth
Amendment 

 EXHIBIT B 

WORK LETTER 
 This
Exhibit is attached to and made a part of the Amendment by and between CENTERPOINT ACQUISITIONS LLC, a Delaware limited liability company (successor in interest to TC Saracen, LLC) (“Landlord”), and REPLIGEN CORPORATION, a Delaware
corporation (“Tenant”) for space in the Building located at 41 Seyon Street, Waltham, Massachusetts. 
 As used in this Workletter, the
“Premises” shall be deemed to mean the Expansion Space as defined in the attached Amendment. 
  

	A.	Landlord has previously presented to Tenant the plan prepared by LaFreniere Architects, dated February 13, 2014, attached hereto as Exhibit B-1 (the “Initial Plan”). Tenant shall deliver to
Landlord as soon as reasonably possible after the Effective Date any comments and revisions Tenant would like to the Initial Plan and the parties shall review and discuss such comments and revisions in good faith in order to agree upon a mutually
acceptable plan for the initial improvements in the Expansion Space. Tenant’s proposed revisions shall use Building Standard methods, materials and finishes and be at least comparable in utility for general office space as provided in the
Initial Plan. Within fifteen (15) Business Days after the Effective Date the parties shall agree upon plans and specifications incorporating Tenant’s revisions that were mutually acceptable to the parties and otherwise consistent with
Initial Plan (the “Plans”). In the event that the parties are unable to agree in good faith on all or any particular changes or revisions, the Initial Plan shall control and shall constitute the “Plans” for all purposes.
The improvements to be performed by Landlord in accordance with the Plans, as further developed and refined into the Construction Drawings (as defined below) are hereinafter referred to as the “Landlord Work.” It is agreed that
construction of the Landlord Work is intended to be “turn-key” and will be completed at Landlord’s sole cost and expense in accordance with the Construction Drawings using Building Standard methods, materials and finishes. Landlord
shall enter into a direct contract for the Landlord Work with a general contractor selected by Landlord. In addition, Landlord shall have the right to select and/or approve of any subcontractors used in connection with the Landlord Work.
Landlord’s Work shall be performed in accordance with the approved Construction Drawings and in compliance with all applicable laws. Landlord’s supervision or performance of any work for or on behalf of Tenant shall not be deemed a
representation by Landlord that the improvements constructed in accordance with the Plans and any revisions thereto will be adequate for Tenant’s use. 

  

	B.	 Landlord shall cause the Plans to be developed into construction level plans and specifications for Landlord Work (the “Construction
Drawings”) and shall deliver the iterations of the Construction Drawings to Tenant for Tenant’s review and approval, which approval shall not be unreasonably withheld, conditioned or delayed so long as the subject Construction Drawings are
consistent with the Plans and prior iterations of the Construction Drawings, and Landlord may disregard any disapproval that is not based on the fact that the subject Construction Drawings are inconsistent with the Plans and prior iterations of the
Construction Drawings or do not comply with law (excluding Tenant Change Orders (as defined below) approved by Landlord). If Tenant fails to respond to the Construction Drawings within three (3) Business Days after delivery of same to Tenant,
Tenant shall be deemed to have approved the same. If Tenant shall request any revisions to the Plans or Construction Drawings, Landlord shall have such revisions 

  
 Exhibit B, Fourth
Amendment 

	 	
prepared and, unless such requested revisions are for purposes of compliance with applicable laws or to conform to the Plans or prior iterations of the Construction Drawings, Tenant shall
reimburse Landlord for the cost of preparing any such revisions to the Plans or Construction Drawings, within thirty (30) days after receipt of an invoice. If Tenant shall request any revisions that are not consistent with the Plans or
Construction Drawings (“Tenant Change Orders”), promptly upon completion of the revisions, Landlord shall notify Tenant in writing of the estimated impact to the Target Expansion Effective Date and the modifications to the costs of
Landlord Work, if any, resulting from such Tenant Change Orders. Tenant, within three (3) Business Days, shall notify Landlord in writing whether it desires to proceed with such Tenant Change Orders. In the absence of such written
authorization, Landlord shall have the option to continue work on the Premises disregarding the requested Tenant Change Orders. Tenant shall be responsible for any Tenant Delay in completion of the Premises resulting from such Tenant requested
Tenant Change Orders, which Tenant Delay shall include, without limitation, the time period reasonably required for Landlord to prepare any required revisions to the Construction Drawings and the period that elapses after Landlord delivers such
revised Construction Drawings until Tenant approves or disapproves same. If such Tenant Change Orders result in an increase in the cost of Landlord Work, such increased costs, plus any applicable state sales or use tax thereon, shall be payable by
Tenant within thirty (30) days after receipt of an invoice. Notwithstanding anything herein to the contrary, all revisions to the Plans shall be subject to the approval of Landlord, which approval shall not be unreasonably withheld, conditioned
or delayed, provided that the Landlord Work as so modified is, in Landlord’s sole but reasonable discretion, generically reusable for office uses after the termination of the Lease, unless Tenant removes such non-generically reusable
improvements and restores the affected area of the Premises to the condition indicated by Exhibit B-1 prior to the expiration of the Term of the Lease and deposits with Landlord, as an additional Security Deposit, an amount reasonably estimated by
Landlord to equal the cost of removing such non-generically reusable improvements and restoring the affected area of the Premises to the condition indicated by Exhibit B-1. Landlord shall respond to such request for revisions within five
(5) Business Days. 

  

	C.	This Exhibit shall not be deemed applicable to any additional space added to the Premises at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of the original Premises
or any additions to the Premises in the event of a renewal or extension of the original Term of the Lease, whether by any options under the Lease or otherwise, unless expressly so provided in the Lease or any amendment or supplement to the Lease.

  
 Exhibit B, Fourth
Amendment 
 Page 2 

 EXHIBIT B-1 

PLANS 
  

 

  
 Exhibit B-1, Fourth
Amendment 

 EXHIBIT C 

TENANT’S RESERVED PARKING SPACES 
  

 

  
 Exhibit C, Fourth
Amendment 

 EXHIBIT D 

RIGHTS OF OTHERS PRIOR TO TENANT’S ROFO RIGHTS 

NONE 

  
 Exhibit D, Fourth
Amendment 

 EXHIBIT E 

FORM OF SNDA 
  

 
  

SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT 

                       
                             , 

Tenant 
 AND 

CANADIAN IMPERIAL BANK OF COMMERCE, 

acting through its New York Branch, 

as Administrative Agent 
  

							
		 	County:	  	Middlesex	  	
		 	State:	  	Massachusetts	  	
				
		 	Premises:	  	41 Seyon Street, 43 Foundry	  	
		 		  	 Avenue and 190 Willow Street

Waltham, Massachusetts

 Dated: as of
                        , 201     

 
  

 
 Record and return by mail to:

 Morrison & Foerster LLP 

1290 Avenue of the Americas 
 New
York, New York 10104 
 Attention: Christopher S. Delson, Esq. 

Exhibit E, Fourth Amendment 

 SUBORDINATION, NON-DISTRURBANCE AND ATTORNMENT AGREEMENT 

THIS AGREEMENT made as of this      day of
                    , 201    , by and among
                        (“Landlord’), CANADIAN IMPERIAL BANK OF COMMERCE, acting through its New York
Branch (“Administrative Agent”), as Administrative Agent for the Lenders (defined below), and
                        (“Tenant”). 

RECITALS: 
 A.
Tenant has executed that certain lease dated                         [as amended by written agreements dated
                        and
                        ] ([collectively, with the amendment{s} thereto,] the “Lease”), with
[                        , predecessor-in-title to] Landlord, as lessor, covering the premises described in the Lease consisting
of approximately a                     square foot space (the “Premises”) in that certain building located at
[                        ]1 Waltham, Massachusetts (the
“Property”) and more particularly described in Exhibit A attached hereto and made a part hereof by this reference; and 

B. Certain lenders (the “Lenders”) have made (or agreed to make) a loan to Landlord secured by a mortgage encumbering the
Property and an assignment of Landlord’s interest in the Lease (said mortgage, together with any amendments, renewals, increases, modifications, substitutions or consolidations of either of them, collectively, the “Security
Instrument”) in favor of Administrative Agent on behalf of the Lenders; and 
 C. Tenant and Administrative Agent desire to confirm
their understanding with respect to the Lease and the Security instrument, and to have Landlord confirm its agreement therewith. 
 NOW,
THEREFORE, in consideration of the covenants, terms, conditions, and agreements contained herein, the parties hereto agree as follows: 

1. The Lease and any extensions, modifications or renewals thereof, including but not limited to any option to purchase, right of first refusal
to purchase or right of first offer to purchase the Property or any portion thereof, if any, is and shall continue to be subject and subordinate in all respects to the Security Instrument and the lien created thereby. 

2. Tenant agrees to deliver to Administrative Agent, in the manner set forth in Paragraph 13 of this Agreement, a copy of any notice of default
sent to Landlord by Tenant. If Landlord fails to cure such default within the time provided in the lease, Administrative Agent shall have the right, but not the obligation, to cure such default on behalf of Landlord within thirty (30) calendar
days after the time provided for Landlord to cure such default in the Lease has expired or, if such default cannot be cured within that time, within a reasonable period provided Administrative Agent is proceeding with due diligence to cure such
default. In such event, Tenant shall not terminate the Lease while such remedies are being diligently pursued by Administrative Agent. Further, Tenant shall not terminate the Lease on the basis of any default by Landlord which is incurable by
Administrative Agent (such as, for example, the bankruptcy of Landlord or breach of any representation by Landlord), provided Administrative Agent is proceeding with due diligence to commence an action to appoint a receiver or to obtain title to the
Property by foreclosure, deed in lieu of foreclosure, or otherwise (collectively, “Foreclosure”). Subject to Administrative Agent’s obligations under Section 3 below, Tenant hereby agrees that no action taken by
Administrative Agent to enforce any rights under the Security Instrument or related security documents, by reason of any default thereunder 
  

 

	1 	Insert as applicable: 41 Seyon Street, 43 Foundry Avenue or 190 Willow Street 

  
 Exhibit E, Fourth
Amendment 

 (including, without limitation, the appointment of a receiver, any Foreclosure or any demand for rent under any
assignment of rents or leases) shall give rise to any right of Tenant to terminate the Lease nor shall such action invalidate or constitute a breach of any of the terms of the Lease. 

3. So long as Tenant is not in default under the Lease beyond applicable notice and cure periods, Administrative Agent shall not disturb
Tenant’s possession and occupancy of the Premises and Tenant’s other rights under the Lease during the term of the Lease. 
 4. If
Administrative Agent or its nominee or designee, or another purchaser of the Property upon a Foreclosure (any such person or entity, a “Successor Owner”) succeeds to the interest of Landlord under the Lease, subject to Tenant’s
performance of its obligations under the Lease within applicable notice and cure periods, the Lease will continue in full force and effect. Thereupon, Successor Owner shall recognize the Lease and Tenant’s rights thereunder and Tenant shall
make full and complete attornment to Successor Owner as substitute landlord upon the same terms, covenants and conditions as provided in the Lease, including, but not limited to, any option to purchase, right of first refusal to purchase or right of
first offer to purchase the Property as may be provided in the Lease. Notwithstanding the foregoing, Tenant agrees that any such option, right of first refusal or right of first offer to purchase the Property or any portion thereof, as may be
provided in the Lease shall not apply to any Foreclosure, as defined herein, and shall not apply to any transfer of the Property by Successor. Owner following such Forecloser. In consideration of the foregoing, Administrative Agent agrees
that any such option, right of first refusal or right of first offer shall not be terminated by any Foreclosure or conveyance of the Property by Successor Owner following such Foreclosure; rather, any such option, right of first refusal or right of
first offer shall remain as an obligation of any party acquiring the Property following the conveyance of the Property by Successor Owner following such Foreclosure. Furthermore, Tenant expressly confirms to Administrative Agent that any acquisition
of title to all or any portion of the Property pursuant to Tenant’s exercise of any option, right of first refusal or right of first offer contained in the Lease shall result in Tenant taking title subject to the lien of the Security
Instrument. 
 5. Tenant agrees that, if Successor Owner shall succeed to the interest of Landlord under the Lease, Successor Owner shall not
be: 
  

	 	(a)	liable for any prior act or omission of Landlord or any prior landlord or consequential damages arising therefrom; or 

  

	 	(b)	subject to any offsets or defenses which Tenant might have as to Landlord or any prior landlord unless Administrative Agent has failed to cure any default by Landlord as herein provided; or 

 

	 	(c)	required or obligated to credit Tenant with any rent or additional rent for any rental period beyond the then current month which tenant might have paid Landlord; or 

 

	 	(d)	bound by any amendments or modifications of the Lease made without Administrative Agent’s or Successor Owner’s prior written consent; or 

 

	 	(e)	liable for refund of all or any part of any security deposit unless such security deposit shall have been actually received by Administrative Agent. 

  
 Exhibit E, Fourth
Amendment 

 6. Tenant agrees that, without the prior written consent of Administrative Agent in each case,
Tenant shall not (a) amend, modify, terminate or cancel the Lease or any extensions or renewals thereof, or tender a surrender of the Lease (except in each case that, upon a default by Landlord under the Lease, Tenant may exercise its rights
under the Lease after giving to Administrative Agent the notice and cure period required by this Agreement), (b) make a prepayment of any rent or additional rent more than one (1) month in advance of the due date thereof, or
(c) subordinate or permit the subordination of the Lease to any lien subordinate to the Security Instrument. Any such purported action without such consent shall be void as against the holder of the Security Instrument. 

7. To the extent that the Lease shall entitle Tenant to notice of the existence of any Security Instrument and the identity of any mortgagee or
any ground lessor, this Agreement shall constitute such notice to Tenant with respect to the Security Instrument and Administrative Agent. 

8. Upon and after the occurrence of a default under the Security Instrument, which is not cured after any applicable notice and/or cure
periods, Administrative Agent shall be entitled, but not obligated, to require that Tenant pay all rent under the Lease as directed by Administrative Agent, which payment shall, to the extent made, satisfy the obligations of Tenant under the Lease.
Landlord agrees to hold Tenant harmless with respect to any such payments made by Tenant to Administrative Agent. 
 9. Nothing in this
Agreement shall impose upon Administrative Agent any liability for the obligations of Landlord under the Lease unless and until Administrative Agent takes title to the Property. Anything herein or in the Lease to the contrary notwithstanding, in the
event that a Successor Owner shall acquire title to the Property or the portion thereof containing the Premises, Successor Owner shall have no obligation, nor incur any liability, beyond Successor Owner’s then interest, if any, in the Property,
and Tenant shall look exclusively to such interest, if any, of Successor Owner in the Property for the payment and discharge of any obligations imposed upon Successor Owner hereunder or under the Lease, and Successor Owner is hereby released or
relieved of any other liability hereunder and under the Lease. Tenant agrees that, with respect to any money judgment which may be obtained or secured by Tenant against Successor Owner, Tenant shall look solely to the estate or interest owned by
Successor Owner in the Property, and Tenant will not collect or attempt to collect any such judgment out of any other assets of Successor Owner. 

10. Except as specifically provided in this Agreement, Administrative Agent shall not, by virtue of this Agreement, the Security Instrument or
any other instrument to which Administrative Agent may be party, be or become subject to any liability or obligation to Tenant under the Lease or otherwise. 

11. EACH OF TENANT, ADMINISTRATIVE AGENT AND LANDLORD HEREBY IRREVOCABLY WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
 12. The provisions of the Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and assigns. The words, “Administrative Agent”, “Landlord” and “Tenant” shall include their respective heirs, legatees, executors, administrators,
beneficiaries, successors and assigns. 

  
 Exhibit E, Fourth
Amendment 

 13. All notices and all other communication with respect to this Agreement shall be directed as
follows: if to Administrative Agent, 200 West Madison Avenue, Suite 2610, Chicago, Illinois 60606, Attention: Real Estate Group, or such other address as Administrative Agent may designate in writing to Tenant; and, if to Tenant, at the address set
forth in the Lease or at such other address as tenant may designate in writing to Administrative Agent. All notices shall be in writing and shall be (a) hand-delivered, (b) sent by United States express mail or by private overnight
courier, or (c) served by certified mail postage prepaid, return receipt requested, to the appropriate address set forth above. Notices served as provided in (a) and (b) shall be deemed to be effective upon delivery or upon refusal
thereof. Any notice served by certified mail shall be deposited in the United States mail with postage thereon fully prepaid and shall be deemed effective on the day of actual delivery as shown by the addressee’s return receipt or the
expiration of three business days after the date of mailing, whichever is earlier in time. 
 14. This Agreement contains the entire
agreement between the parties and no modifications shall be binding upon any party hereto unless set forth in a document duly executed by or on behalf of such party. 

15. This Agreement may be executed in multiple counterparts, all of which shall be deemed originals and with the same effect as if all parties
had signed the same document. All of such counterparts shall be construed together and shall constitute one instrument. 
 [Remainder of Page
Intentionally Left Blank; Signature Page Follows] 

  
 Exhibit E, Fourth
Amendment 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and
year first above written. 
  

			
	CANADIAN IMPERIAL BANK OF COMMERCE, acting through its New York Branch, as Administrative Agent for the Lenders
		
	 By:
	 	 
		 	 Name:

		 	 Title:

  
 Exhibit E, Fourth
Amendment 

 
			
	 [TENANT]

		
	 By:
	 	 
		 	 Name:

		 	 Title:

  
 Exhibit E, Fourth
Amendment 

			
	 AGREED AND CONSENTED TO:

	
	 LANDLORD

	
	 CENTERPOINT ACQUISITIONS, LLC,

a Delaware limited liability & company

	
	

  
 Exhibit E, Fourth
Amendment 

 ACKNOWLEDGEMENT 
  

											
	STATE OF	 	 	  	)	    		  		  	
		 		  		    	) SS.	  		  	
	COUNTY OF 	 	 	  	)	    		  		  	

 On the         day
of                 in the year 201    , before me, the undersigned, personally appeared
                , personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and
acknowledged to me that [s/he] executed the same in his capacity as Authorized Signatory, of CANADIAN IMPERIAL BANK OF COMMERCE, acting through its New York Branch as Administrative Agent for the Lenders, and that by [her/his] signature on
the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument. 
  

	
	   

	Notary Public

  

			
		
	My commission expires:	 	 
	
	 

  

  
 Exhibit E, Fourth
Amendment 

 ACKNOWLEDGEMENT 
  

									
	STATE OF	 	 	  	)	  		  	
		 		  	) SS.	  		  	
	COUNTY OF	 	 	  	)	  		  	

 I, a Notary Public in and for said County, in the State aforesaid, DO HEREBY CERTIFY
that                 as                 of CENTERPOINT ACQUISITIONS, LLC, a
Delaware limited liability company, appeared before me this day in person and acknowledged that he signed and delivered said instrument as his own free and voluntary act and as the free and voluntary act of said entities for the uses and purposes
therein set forth. 
  

	
	   

	Notary Public

  

			
		
	My commission expires:	 	 
	
	 

  

  
 Exhibit E, Fourth
Amendment 

 ACKNOWLEDGEMENT 
  

											
	STATE OF	 	 	  	)	    		  		  	
		 		  		    	) SS.	  		  	
	COUNTY OF 	 	 	  	)	    		  		  	

 I, a Notary Public in and for said County, in the State aforesaid, DO HEREBY CERTIFY that
                as                 of
                , a                      appeared before me this day
in person and acknowledged that he signed and delivered said instrument as his own free and voluntary act and as the free and voluntary act of said
                    , for the uses and purposes therein set forth. 

 

	
	   

	Notary Public

  

			
		
	My commission expires:	 	 

  
 Exhibit E, Fourth
Amendment 

 EXHIBIT A 

Legal Description of Property 
 Lot A
(UNREGISTERED LAND) 
 A certain parcel of land in Waltham, Middlesex County, Massachusetts, westerly of Seyon Street, northerly of Boston and Maine
Railroad, easterly of Willow Street and southerly of Grove Street, being shown as Lot A on a plan entitled “CenterPoint Project Merger of Plan of Land in Waltham, Massachusetts, Middlesex County”, dated January 28, 2013, prepared by
DGT Survey Group, to be recorded with Middlesex South Registry of Deeds herewith, and being more particularly described as follows: 
 Beginning at the
intersection of the westerly side of Seyon Street with the northerly side of the former Boston and Maine railroad location, thence running: 
  

					
	 N 52-08-34 W
	 	203.28 feet	  	to a point of curvature; thence
			
	 Westerly
	 	20.00 feet	  	by a curve to the left of 1750.76 foot radius to a point of non-tangency, the last two courses being by land now or formerly of Boston & Maine Corporation; thence
	 S 37-12-10 W
	 	16.50 feet	  	in part by said land of the former Boston & Maine Corporation and in part by land now or formerly of Colonial Shopping Center, Inc. to a point of non-tangency; thence
			
	 Westerly
	 	119.43 feet	  	by a curve to the left of 1734.26 foot radius to a point of compound curvature, being by said land of Colonial Shopping Center; thence
			
	 Westerly
	 	457.86 feet	  	by a curve to the left of 1121.09 foot radius to a point of non-tangency, being in part by said land of Colonial Shopping Center, Inc. and in part by land now or formerly of Anthony G. Cardillo, Jr. and Joseph J. Cardillo;
thence
			
	 N 78-04-22 W
	 	25.15 feet	  	thence
			
	 N 73-45-26 W
	 	66.87 feet	  	to a point of non-tangency, the last two courses being by said land of Anthony G. Cardillo, Jr. et al; thence
			
	 Westerly
	 	114.07 feet	  	by a curve to the left of 1310.85 foot radius to a point of non-tangency; thence
			
	 N 85-43-49 W
	 	110.48 feet	  	to a point of non-tangency; thence
			
	 Westerly
	 	21.28 feet	  	by a curve to the left of 1318.10 foot radius to a point of tangency; thence
			
	 S 87-10-56 W
	 	53.54 feet	  	to the easterly side of Willow Street, the last four courses being by land now or formerly of Sadle M. Cardillo and Anthony G. Cardillo, Jr.; the last eleven courses being also by said Boston and Maine railroad location;
thence

  

  
 Exhibit B-1 Fourth
Amendment 

					
			
	 N 26-44-06 E
	 	172.66 feet	  	by Willow Street; thence
			
	 S 63-36-26 E
	 	35.87 feet	  	by land now or formerly of Raytheon Company; thence
			
	 S 62-06-32 E
	 	64.14 feet	  	thence
			
	 N 26-44-06 E
	 	1.68 feet	  	the last two courses being by land now or formerly of Willow Street Trust; thence
			
	 S 63-36-26 E
	 	2.07 feet	  	thence
			
	 N 25-08-10 E
	 	73.58 feet	  	thence
			
	 N 63-36-26 W
	 	100.02 feet	  	to the easterly side of Willow Street, the last three courses being by land of said Raytheon Company; thence
			
	 N 26-44-06 E
	 	185.87 feet	  	by Willow Street to a point of curvature at Foundry Avenue; thence
			
	 Easterly
	 	15.60 feet	  	by a curve to the right of 10.00 foot radius to a point of non-tangency; thence
			
	 S 63-52-04 E
	 	454.36 feet	  	the last two courses being by the southerly side of Foundry Avenue; thence
			
	 N26-07-56 E
	 	40.00 feet	  	by the easterly end of Foundry Avenue; thence
			
	 N 63-52-04 W
	 	192.40 feet	  	by the northerly side of Foundry Avenue; thence
			
	 N 26-17-50 E
	 	293.83 feet	  	in part by land now or formerly of John Sottile, in part by land now or formerly of Noviens Lane Nominee Trust, in part by the easterly end of Noviens Lane, in part by land now or formerly of Pak Chau Chan and Chan Vuong and in part
by land now or formerly of Anjo Realty Trust; thence
			
	 S 62-14-54 E
	 	250.01 feet	  	thence
			
	 S 62-14-54 E
	 	32.02 feet	  	thence
			
	 S 63-59-24 E
	 	8.00 feet	  	thence
			
	 S 62-54-32 E
	 	316.29 feet	  	to a stone bound with drill hole; thence
			
	 N 25-58-32 E
	 	619.17 feet	  	to the southerly side of Grove Street, the last five courses being by land now or formerly of Standard Thomson Corporation; thence
			
	 S 67-07-36 E
	 	516.92 feet	  	to a point of curvature; thence
			
	 Easterly
	 	90.21 feet	  	by a curve to the left of 1942.98 foot radius to a rounding at Seyon Street, the last two courses being by Grove Street; thence
			
	 Easterly and southerly
	 	59.26 feet	  	by a curve to the right of 30.00 foot radius by said rounding at Seyon Street to the westerly side of Seyon Street; thence
			
	 S 43-23-26 W
	 	753.60 feet	  	thence
			
	 S 40-33-56 W
	 	553.97 feet	  	to the point of beginning, the last two courses being by Seyon Street.

 TOGETHER WITH rights contained in the following: 
  

	A.	Bridge Switchgear and Fire Loop Easement Agreement dated February 28, 2001 recorded with said Deeds in Book 32455, Page 291 and filed with said Land Court as Document No. 1164263; as affected by First
Amendment to Bridge, Switchgear and Fire Loop Easement Agreement dated December 16, 2005 recorded with said Deeds in Book 46700, Page 38. 

  

  
 Exhibit E, Fourth
Amendment 

	B.	Grant of Easement made by and among Colonial Shopping Center, Inc., I-Park West Seyon LLC and Raytheon Company dated November 17, 2005 recorded with said Deeds in Book 46652, Page 431. 

 

	C.	Access Easement Agreement made by and between Grove Willow LLC and Raytheon Company dated as of December 30, 1999 and recorded with said Deeds in Book 31018, Page 1 as affected by the following: 

Amendment to Access Easement Agreement dated December 19, 2005 and recorded with said Deeds in book 46712, Page 292. 

Second Amendment to Access Easement Agreement dated December 18, 2007 and recorded with said Deeds in Book 50547, Page 37. 

Affidavit dated December 31, 2007 and recorded with said Deeds in Book 50547, Page 40. 

Amendment to Access Easement Agreement concerning 3.46 Acre Parcel dated March 27, 2008 and recorded with said Deeds in Book 51404, Page
1. 
 Amendment to Access Easement Agreement Concerning LIG Parcel dated April 3, 2008 and recorded with said Deeds in Book 52219, Page
319. 
 Third Amendment to Access Easement Agreement dated June 12, 2009 and recorded with said Deeds in Book 53017, Page 468. 

 

  
 Exhibit E, Fourth
Amendment

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]